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Abstract
Hepatitis C virus (HCV) infection accounts for approximately 40% of chronic liver
disease in the United States and results in an estimated 8,000-10,000 deaths annually.
Simulations suggest that in the next decade morbidity and mortality associated with HCV
infections will result in approximately 200,000 deaths and direct medical expenditures of
over $10 billion. Furthermore, recent WHO estimates of worldwide prevalence suggest that
up to 2% of the world population is infected with HCV, representing between 120 and 200
million people.
For reasons that are still poorly understood, the current standard of care is effective
only in a subset of patients, and depends on both patient-related and disease-related
characteristics. Sustained virological response (SVR) - HCV RNA in patient plasma drops
below detectable levels at week 24 following completion of treatment, which is thought to
be indicative of curing the disease - is attainable in only ~50% of patients.
In recent years, HCV production has been shown to be inextricably linked to lipid
metabolism and to the secretion of very low density lipoproteins (VLDL) from hepatocytes.
This suggests that by modulating lipid metabolism in the cell, viral production may be
reduced in a clinically relevant manner. This work begins by characterizing the link between
VLDL secretion and HCV production in the Huh7.5.1/JFH-1 system.
We proceed to examine the effects of naringenin, a grapefruit flavonoid, on the
production of HCV. Naringenin has been shown previously to reduce VLDL secretion from
hepatocytes, and we demonstrate its ability to block HCV production, as well. We explore
the mechanism of naringenin's effect on HCV, and show that the flavonoid prevents the
assembly of infectious viruses in the cell.
Despite previous success by several groups in describing the mechanisms involved in
naringenin's effect on VLDL secretion, these mechanisms are thought to account only for
~50% of the observed inhibition, suggesting a deeper understanding of the underlying
principals is still lacking. We suggest that naringenin exerts its metabolic, and consequently,
antiviral effects through modulation of nuclear recepetor (NR) activity. NRs are a
superfamily of ligand-regulated transcription factors known to have an important role in
maintaining the homeostasis of metabolites. We show that naringenin activates peroxisome
proliferator activated receptors (PPARs), NRs known to drive P-oxidation; and inhibits the
liver X receptor (LXR), known to drive lipogenesis and cholesterol synthesis.
Despite naringenin's promise as a possible treatment for HCV, its low bioavailability,
limits its clinical potential. We conclude this work by showing that naringenin's solubility
and bioavailability - and thus, clinical relevance - can be greatly enhanced by complexation
with p-cyclodextrins.
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1 Introduction
1.1 Hepatitis C Virus
Hepatitis C virus (HCV) infection accounts for approximately 40% of chronic liver disease
in the United States and results in an estimated 8,000-10,000 deaths annually.
Simulations suggest that in the next decade morbidity and mortality associated with
HCV infections will result in approximately 200,000 deaths and direct medical
expenditures of over $10 billion (1). Furthermore, recent WHO estimates of worldwide
prevalence suggest that up to 2% of the world population is infected with HCV,
representing between 120 and 200 million people (2). In the developed world, most
new cases are acquired through blood-to-blood transmission (i.e., needle sharing) (3).
The natural history of hepatitis C infections is highly variable between patients
(Figure 1) (3). 75-85% of all infected individuals develop a long-term infection, while
approximately 15% clear the infection following the acute phase. The chronic phase of
the disease is asymptomatic for an extended period, and may remain so. However, 10-
15% of chronic patients develop fibrosis and cirrhosis of the liver, usually over several
decades. Approximately 6% of patients with cirrhosis will then develop decompensated
liver disease and will require transplant. Consequently, HCV infection is the leading
indication of liver transplant in the US and most parts of the world (4). Lastly, patients
with established cirrhosis have a 3-4% annual risk of developing hepatocellular
carcinoma (HCC). The exact reasons for the variability in natural history among
individuals have not been entirely clarified, but associations with multiple demographic
factors, co-morbidities, and behavioral factors have been described (3).
Initial infection
(100%)
ChronicResolIve hepatitis(15%) (85%)
Stable Cirrhosis
(86%) (17%)
Compensated Mortality
(13%) (4%)
Figure 1 - HCV has a highly variable natural history. For every 100 people infected, 85 will develop
chronic hepatitis. In the majority of these, the disease will be stable, but over several decades, 17 people
will develop liver fibrosis and cirrhosis. These people will be at an increased risk for decompensated liver
disease and hepatocellular carcinoma. The factors that lead patients to have such variable courses of
disease are not known, although several associations have been made to demographic factors, co-
morbidities, and behavioral factors. More recently, genetic links have been invistagted. Adaptedfrom
McHutchison (2004).
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Since the discovery of the HCV virus in 1989 (5), the standard of care for treating
HCV-infected individuals has developed from interferon c (IFNa) monotherapy through
a combination of ribavirin and interferon, to the current standard of pegylated IFNa and
ribvirin (6). For reasons that are still poorly understood, this regimen is effective only in
a subset of patients, and depends on both patient-related and disease-related
characteristics (7). Sustained virological response (SVR) - HCV RNA in patient plasma
drops below detectable levels at week 24 following completion of treatment, which is
thought to be indicative of curing the disease - is attainable in only 42-46% of genotype
1 infections, the most common genotype in the US and Europe (6, 8). Beyond its low
efficacy, combination treatment exacts a high toll in terms of drug-induced side effects,
including flu-like illness, fever, fatigue, hematological disease, anemia, leucopenia,
thrombocytopenia, alopecia, and depression (9). These adverse effects, along with other
barriers, prevent the completion of treatment in patients, leading to discontinuation of
treatment in 10-20% of cases.
Several drugs are currently in development for HCV to improve efficacy and
reduce adverse effects. Most efforts focus on inhibiting viral enzymes, specifically the
viral protease and polymerase (see below), although attempts have been made to
develop nucleic acid-based treatments (6). The propensity of the virus to mutate,
however, makes it difficult to consistently produce an SVR in patients. Previous drug
candidates have led to the evolution of escape mutants within patients (quasi-species)
and could lead to the evolution of resistant strains in the patient population (10, 11).
Strategies borrowed from the treatment of HIV, including timing of treatments and drug
cocktails hold some promise in averting the development of resistance (12).
Nonetheless, therapies that target host factors hold more promise, as these are
immutable. Specifically, agents are being developed to either elicit an immune response
against the virus (13), or to exploit the virus' dependence on certain host factors for the
completion of its lifecycle (14, 15).
1.1.1 The Viral Life Cycle
HCV is an enveloped, ~9500 bp, positive-strand RNA virus, a member of the
Flaviviridae family. The viral genome encodes a single open reading frame (ORF) of
approximately 3000 amino acids. The viral life cycle begins upon entry into the host cell
(Figure 2). The process of cellular entry has yet to be clarified completely, but seems to
involve several receptors. Both CD81 (16) and claudin-1 (17) seem to be required for
successful entry of the virus into the cell. It seems however, that these receptors are
involved in later steps of viral entry, and that early steps may involve either the low-
density lipoprotein receptor (LDLR) or the scavenger receptor, SR-BI (16, 18, 19).
Upon introduction of the viral genetic material into the host cytoplasm,
translation is initiated via the viral 5' nontranslated region (NTR), which functions as a
ribosomal entry site (20). The viral polyprotein is threaded in and out of the
endoplasmic reticulum (ER), and is then cleaved both by host enzymes and
autocatalytically by proteases that are part of the nascent polyprotein. This leads to the
production of mature structural proteins, including core, El, and E2; and nonstructural
(NS) proteins (21, 22). The accumulation of viral proteins, and specifically core protein,
in the cellular ER induces morphological changes in the cell with the formation of a
membranous web, where viral replication has been reported to occur (23). HCV budding
occurs either at the ER membrane or in ER-associated lipid droplets (see below) (24) and
is driven by the viral core protein (24, 25), after which the virus is exported from the cell
via the Golgi apparatus by exocytosis (26).
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Figure 2 - Illustration of the viral lifecycle. (Top) Cell entry (1) has been shown to be dependent on
several receptors, including SR-BI, LDLR, CD81, and claudin-1. It is not clear whether receptors recognize
a lipoviral particle (a virion physically associated with a lipoprotein), or whether the interaction occurs
with virions directly. Viruses enter the cytoplasm and uncoat (2), and their RNA is used to synthesize the
viral polyprotein (3). This induces the formation of the membranous web, which is closely associated
with lipid droplets. The viral replication complex (4) has been reported to be associated with both of
these ER-related structures. Finally, the sense strand genome and structural proteins are assembled into
an infectious virion (5), probably as a lipoviral particle, which exits the cell via the Golgi apparatus by
exocytosis (6). ER/MW - endoplasmic reticulum/membranous web. (Bottom) The viral polyprotein
depicted inserted into the ER membrane.
1.1.2 Viral particle production is dependent on host metabolic processes
The link between HCV and lipid metabolism was suggested early on, both by the
association of steatosis with chronic HCV infection (27), and the finding that HCV
particles are physically associated with lipoporoteins in patient plasma (28). Early
experiments were limited by the lack of a cell culture system capable of sustaining the
full viral life cycle. Nonetheless, the HCV core protein expressed in HepG2 hepatoma
cells was shown to associate with cytoplasmic lipid droplets (29) - lipid storage
organelles that are closely associated with the ER (30). Furthermore, viral replication in
replicon-based systems was shown to be inhibited by statins, inhibitors of HMG CoA, the
rate-limiting enzyme in the mevalonate pathway (31, 32). Further investigation revealed
that this was due to the dependence of viral replication on the availability of
geranylgeranyl (33). This lipid was shown to be required in order to anchor the FBL2
protein to the ER membrane, and that interaction of the viral NS5A protein with the
anchored FBL2 was essential for viral replication (34). Lastly, it was observed that livers
of chimpanzees infected with HCV showed steatotic changes and changes in gene
expression consistent with pro-lipogenic metabolic changes (35), provided further
evidence of the link between HCV and altered lipid metabolism.
The development of the Huh7.5.1 cell line capable of supporting the full life cycle
of JFH-1-derived HCV strains (36, 37) has allowed the further elucidation of both the
dependence of the HCV lifecycle on lipid metabolism, and of the alterations in cellular
metabolism as a consequence of HCV infection. Huang et al. demonstrated that HCV
assembled in vesicles enriched in ApoB, the main protein component found in very low-
density lipoprotein (VLDL); and in microsomal triglyceride transfer protein (MTP), the
rate-limiting enzyme in VLDL assembly (Figure 3) (38). Using a similar system,
Gastaminza et al. demonstrated the existence of high density intracellular HCV
precursors suggesting the virus binds to low density lipoproteins in the ER to form
lipoviral particles (39). Lastly, HCV has been found to be actively secreted while bound
to (VLDL), and blocking the production of ApoB using RNAi or by inhibiting MTP has
been shown to lead to a decrease in the amount of secreted virus (38).
Conversely, there is evidence to suggest that chronic viral infection is correlated
with the development of steatosis, especially in HCV genotype 3 (40). Yang et al. showed
that the HCV core protein leads to the upregulation of the fatty acid synthase gene (41),
and others have shown an upregulation of the lipogenic SREBP-1c signaling pathway (42,
43). Significantly, HCV has been shown to regulate nuclear receptors (NRs; see below), a
family of ligand-activated transcription factors, which function as master regulators of
cellular metabolic processes (44). HCV core associates with RXRa, a transcriptional co-
regulator of multiple metabolic processes (45), and downregulates the PPARC NR, a
known driver of fatty acid 1-oxidation (46), leading to downregulation of the rate-
limiting enzymes CPT-1 and AOX. Studies of liver biopsies of chronic HCV patients
suggest these effects occur in situ, as well (40). Furthermore, HCV core protein has been
recently shown to enhance the activity of the pro-lipogenic LXRc NR (43). Interestingly,
the hepatitis B viral X protein has recently been shown to activate LXRa, suggesting the
possibility of a more general mechanism for virus-cell interaction in the liver (47, 48).
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Figure 3 - VLDL assembly in the ER-Golgi. Nascent ApoB is threaded into the ER lumen, where it becomes
associated with triglycerides (TG) and cholesteryl esters (CE). Microsomal triglyceride transfer protein
(MTP), the rate-limiting enzyme in VLDL assembly, actively transports TGs into the ER. In the absence of
TG and CE, ApoB is co-translationally degraded, preventing an accumulation of ApoB in the ER and the
export of VLDL. A pre-VLDL particle is exported from the ER to the Golgi apparatus, where it fuses with
bulk TGs in the form of lipid droplets, forming the mature VLDL particle which is then exported from the
cell by exocytosis (49, 50). Adapted from Ikonen (2008).
This evidence suggests that infectious particle production is inextricably linked to
lipid metabolism and to the secretion of VLDL from hepatocytes. This hypothesis is both
consistent with the above-mentioned observations, and may explain the tropism of the
virus. Furthermore, by modulating lipid metabolism in the cell, viral production may be
reduced in a clinically relevant manner.
1.2 Host lipid metabolism is controlled by a family of nuclear receptors
Over the past decade, a superfamily of proteins called nuclear receptors (NRs) has been
identified and characterized. This family of receptors is involved in embryonic
development, cell death, and maintenance of cellular differentiation (51). Among their
many functions, NRs have an important role in maintaining the homeostasis of
metabolites (52).
All NRs share a similar, modular structure, with three major domains (53). The N-
terminal domain is known as the transactivation domain, which allows the NR to
interact with coactivators and other transcription factors. The central, DNA binding
domain (DBD) allows the NR to recognize response elements in specific genes. Lastly, the
C-terminal, ligand binding domains (LBDs) of all NRs share a common structure. The LBD
is generally constructed of a core of 11 helices and a twelfth helix (H12) that forms a lid
structure over a binding pocket in the core. The orientation of H12 is determined by the
ligand that is bound to the core of the LBD. In the absence of a ligand, the conformation
of H12 allows the NR to bind co-repressors; while ligand binding leads to an allosteric
shift that allows co-activators to interact with the LBD and the transactivation domain.
Several barriers complicate the study of NR activities in cells. First, nuclear
receptors regulate gene function through interactions with multiple co-repressors and
co-activators, whose function is often cell-specific and condition-specific (54). Second,
NRs are known to be phosphoproteins, and are regulated by multiple kinases (55). Third,
nuclear receptors are known to regulate each other's function through transcriptional
(56) and non-transcriptional (e.g., competitive inhibition) mechanisms (57, 58). Lastly,
the LBDs of several NRs have been shown to be flexible in accommodating multiple
ligands, leading to conformational changes that exert differential regulatory effects (59-
63). Nonetheless, the benefits of understanding and controlling NR function is evident
when considering their involvement in a plethora of disease states, such as cancer,
infertility, diabetes, and obesity (64); and the success of therapeutic agents that target
these receptors: tamoxifen for the estrogen receptor (65, 66), fibrates for PPARax,
thiazolidinediones (TZDs) for PPARy (67, 68), and dexamethasone for the glucocoticoid
receptor (44).
1.2.1 Three families of NRs control metabolism
Within the complex web of interacting NRs, three major families are involved in
the regulation of lipid and carbohydrate metabolism (Table 1): peroxisome proliferator-
activated receptors (PPARs), which bind fatty acids; liver X receptors (LXRs), which are
known to bind both glucose and products of the mevalonate pathway, most notably
cholesterol derivatives; and farnesoid X receptor (FXR), which binds bile salts (44).
Name Abbreviation Nomenclature Ligand
Peroxisome proliferator- PPARc NR1C1 Fatty acids, leukotriene
activated receptor B4, fibrates
PPARP/6 NR1C2 Fatty acids
PPARy NR1C3 Fatty acids
prostaglandin J2
Liver X receptor LXRa NR1H3 Oxysterols, T0901317,
GW3965, glucose
LXRP NR1H2 Oxysterols, T0901317,
GW3965
Farnesoid X receptor FXRa NR1H4 Bile acids, fexaramine
Members of these three families are differentially expressed in various tissues,
and their activation has been reported to lead to different responses - contrary
responses, when viewed at the level of the single cell - in different tissues and cell types
(54, 69). Importantly, when viewed from the point of view of the organism, the different
effects exerted by similar stimuli (i.e., metabolite abundance) should lead to differing
responses in different tissues. For example, low glucose levels should signal adipocytes
to mobilize fat back to the liver (i.e., fat secretion), while signaling the liver to take up
and break down lipid (70).
Two NR families - the PPARs and LXRs - sense opposing metabolic states, driving
different transcriptional programs in the organism (69, 70). The PPAR family of NRs
includes PPARc, PPARy, and PPAR6 (71). The prevalence of these receptor subtypes
varies in different tissues, with PPARa being the most prevalent subtype in the liver, and
PPARy the most abundant in adipose tissue (72). PPARa is activated by fatty acids
released in a physiologicalfasting state, leading to increased p-oxidation and
gluconeogenesis (73). PPARa agonists in particular are known to upregulate genes
involved in the s-oxidation of fatty acids and gluconeogenesis (74). PPARy is similarly
activated by long-chain fatty acids and certain prostaglandins, and leads to increased
storage of fat in adipocytes (75). In clinical practice, PPARa agonists (fibrates) are used
to treat hyperlipidemia, whereas PPARy agonists (TZDs) are used to increase insulin
sensitivity (68, 76).
The LXR family of NRs includes both LXRct and LXRP (77-79). The latter is
ubiquitously expressed, while the former is found primarily in the liver, adipose tissue,
and macrophages and is activated by the abundance of glucose and sterols (80), typical
of a physiological fed state. Following activation by its ligands, LXRa activates lipogenic
and glycolytic genes, including genes involved in the production of VLDL and its
secretion by hepatocytes (81), partly through activation of SREBP-1c (82, 83).
Following the binding of an agonist, both PPARs and LXRs become activated and
heterodimerize with another NR, the retinoid X receptor (RXR) (44). The activated
heterodimer then binds conserved response elements in specific genes, while recruiting
other co-regulatory molecules, such as the co-activators PGC1a (84) and Trap220 (85)
for PPARa and LXRa, respecitvely. The requirement of both LXR and PPAR for the RXR
binding partner leads to competitive inhibition at the level of receptor activation,
offering a transcriptional layer of control over fasted-to-fed transition (57, 58, 86). The
existence of both a PPAR response element (PPRE) and an LXR response element (LXRE)
in the regulatory region of the LXRa gene (56, 87) suggests further levels of cross-
regulation. Lastly, other coactivators, corepressors and kinases, such as P13K and ERK,
can regulate NR activity by non-transcriptional mechanisms (Figure 4) (54, 55, 88).
Figure 4 - Lipid and carbohydrate metabolism signaling network. Some of the important regulators of
lipid vs. glucose neogenesis mentioned in the text are presented. LXRa, PPARa, and FXRa are master
regulators of lipid and cholesterol metabolism. The induction of LXRa leads to the activation of SREBP-1c
and other pathways leading to the production of fat and cholesterol; whereas activation of PPARa leads
to gluconeogenesis. FXR stimulation induces the conversion of cholesterol into bile salts. The three NRs
bind with RXR resulting in transrepression between PPARa and LXRa due to their need for RXR binding in
order to become fully active. This diagram captures only a few of the multiple interacting regulators of
metabolism in the cell, and is meant to illustrate the high level of complexity related to NR metabolic
regulation. Created using Ingenuity Pathways Analysis software package (Ingenuity systems, Redwood
City, CA).
Given the control these NRs exert over lipid metabolism, and given the
association between the HCV life cycle and lipid metabolism, we hypothesize that
modulating the activities of these NRs will allow the modulation and suppression of HCV
production.
1.3 Naringenin
Naringenin is part of a 4000-member polyphenolic family of structurally related
molecules called flavonoids (Figure 5) (89). More specifically, naringenin belongs to a
class called flavonones, members of which are commonly found in citrus fruits.
Naringenin is highly insoluble in water, and is found as a glycoside conjugate, naringin
(naringenin-7-rhamnoglucoside), in grapefruit. Naringenin has been reported to be an
antioxidant with demonstrated hypolipidemic, anti-carcinogenic and anti-inflammatory
properties (89). Naringenin is known to interact with multiple drugs as a result of its
competitive inhibition of cytochrome P450 enzymes (90).
Figure 5 - Naringenin is a flavonoid. Naringenin (top left) is a molecule of the flavonone class. Related
molecules share the flavonoid backbone structure (top right). Many flavonoids are secondary plant
metabolites and are attached to glycones (sugar moieties). Indeed, naringenin is naturally found in
plants - most abundantly in grapefruits - as naringin (bottom) and is hydrolyzed to its aglycone form in
the intestine.
1.3.1 Naringenin reduces VLDL secretion
Naringenin has previously been shown to reduce the secretion of VLDL by
inhibiting several signaling and metabolic pathways (91). Given the dependence of HCV
on the secretion of VLDL, this suggests naringenin could be used to inhibit the production
of virus in hepatocytes.
The molecular mechanism behind naringenin's hypolipidemic effect was studied
mainly in HepG2 cells, where naringenin was shown to reduce the secretion of VLDL and
LDL (92, 93) through the inhibition of ACAT2 and MTP (92, 94), critical enzymes for VLDL
assembly. Allister et al. demonstrated that this inhibition is regulated primarily through
the mitogen-activated protein kinase pathway, through MEK1/2 and ERK1/2 (94). In
addition, naringenin was shown to induce LDL receptor (LDL-R) (95), whose expression
in the ER leads to the degradation of ApoB (96, 97). This upregulation of LDL-R
transcription was shown to be caused by activation of P13K upstream of SREBP-1 (95).
Naringenin was also shown to inhibit HMGR (98), while activating enzymes important in
fatty acid oxidation such as CYP4A11 (99).
Despite the success in describing some of the mechanisms involved in
naringenin's effect on VLDL secretion, these mechanisms are thought to account onlyfor
~50% of the observed inhibition (100), suggesting a deeper understanding of the
underlying principals is still lacking.
1.3.2 Polyphenols interact with nuclear receptors
In recent years, research has elucidated the mechanisms of action of multiple
natural products, in particular, plant-derived polyphenolic compounds. A large number
of plant-derived compounds have been found to modulate the activities of NRs, notably
those of the PPAR, LXR, and FXR families (101). The myriad effects of naringenin in cells,
suggest that theflavonoids may also target nuclear receptors.
Strengthening this hypothesis is the anecdotal report that naringenin interacts
with LXR (95) and more recently that it activates PPARct in U-20S cells (102). A similar
pathway was demonstrated for green tea polyphenols and soy isoflavones which
regulate LXRa and PPARct (101). The understanding that nuclear receptors are regulated
to some degree by kinases of the MAPK and P13K/Akt pathways through
phosphorylation could provide a link between previously described mechanisms and a
NR-mediated mechanism.
1.3.3 Naringenin pharmacokinetics and toxicity
Following enteral administration, naringin is hydrolyzed to its aglycone form, naringenin,
either by gut flora or intestinal enzymes prior to being absorbed in the intestine (103).
Intestinal flora has also been shown to degrade naringenin to other metabolites, such as
4-hydroxbenzoic acid (104, 105). Naringenin's low solubility in aqueous environments is
thought to contribute to its low bioavailability: in clinical trials, plasma concentrations
have not been reported to exceed 6[tM (89, 106). The flavonoid is conjugated either in
the intestine or in the liver to a glucuronide form (107), and is finally metabolized by the
hepatic CYP1A enzyme (108).
Limited information is available regarding naringenin's toxicity. Notably, as a
naturally-derived product, the flavonoid is marketed as a food supplement. In rats, its
oral LD50 has been reported to be >5000 mg/kg (109), and in human studies, naringenin
was administered at oral doses of up to 2g without any adverse effects (110). In vitro
toxicity has been demonstrated to be low in several cell types, with cell growth IC50
values of >1mM (89).
1.3.4 Cyclodextrins could improve naringenin's low bioavailability
Naringenin's anti-atherogenic and anti-inflammatory properties, along with its antiviral
potential, make it an interesting candidate for clinical application. As with other drugs,
however, efficacy depends on the ability to reproducibly deliver the molecule to
patients (111). The ability to breakdown naringin to the absorbable naringenin form
varies widely between patients, possibly owing to differences in gut flora (106). Thus, a
method of enhancing the bioavailability of naringenin itself is required.
Cyclodextrins are a family of cyclical oligosacchrides, composed of varying
numbers of glucopyranoside rings that form a three-dimensional toroid structure. The
inner face of the toroid is significantly less hydrophilic than the surrounding water,
providing an energetic advantage to the insertion of hydrophobic molecules into the
cavity. P-cyclodextrins, specifically, are composed of seven sugar rings, and have been
shown to be non-toxic to humans (112). These cyclodextrins are widely used in the food
and pharmaceutical industries as excipients to enhance the solubility of hydrophobic
molecules.
The potential of P-cyclodextrins to enhance the solubility and gut absorption of
flavonoids was demonstrated by Uekama and coworkers (113). The researchers
complexed the flavonoid-glycoside, rutin, with HPPCD, and found an >10-fold increase
in its solubility in aqueous solution. Plasma concetration, as measured by area-under-
the-curve (AUC), increased nearly 3-fold. Several effects could explain an increased rate
of transport following complexation with HPICD, including enhancement of dissolution
kinetics, increase in solubility, decrease in degradation kinetics in the gut, change in the
properties of the intestinal membrane, and shuttling and enhancement of drug
concentration at the intestinal wall (Figure 6) (114, 115). Notably, HPPCD, particularly, is
known to cause very little irritation to the gut mucosa and is used in multiple
preparations (116).
The hydrophobic nature of naringenin, and its structural similarity to the
hydrophobic quercetin unit in rutin, suggests that its delivery could similarly be enhanced
through complexation with HP3CD.
Gut lumen
Naringer in-CD
Bacteria
Figure 6 - Enhanced absorption of naringenin in the gut. Complexation of a small, hydrophobic molecule
such as naringenin with cyclodextrin (CD) could lead to enhanced absorption by several means. (1)
Complexation could shift the thermodynamic balance and enhance the kinetics of dissolution. (2) CD
could limit the amount of naringenin that is exposed to degradation by gut microbes. (3) Naringenin could
alter the properties of the intestinal wall microenvironment or of the wall itself. CD complexation is not
expected to affect post-absorption steps, as CD does not cross the intestinal wall.
1.4 This thesis
The sum of this work suggests that naringenin may be useful in the treatment of HCV.
We will first examine the mechanism underlying the flavonoid's effects on HCV
production and show it is due to its inhibition of VLDL production. We demonstrate that
naringenin blocks the assembly of infectious particles. We then show that naringenin's
metabolic, and consequently, anti-viral effects can be attributed to its effect on nuclear
receptors. Finally, we demonstrate that through complexation with P-cyclodextrins, the
molecule can be delivered in a clinically relevant manner.
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2 Apolipoprotein B-dependent hepatitis C virus secretion is
inhibited by the grapefruit flavonoid naringenin
2.1 Introduction
HCV has long been known to associate with circulating lipoproteins (1), and its
interactions with the cholesterol and lipid pathways have been recently described (2). In
this work, we demonstrate that HCV is actively secreted by infected cells through a
Golgi-dependent mechanism while bound to very low density lipoprotein (VLDL).
Silencing apolipoprotein B (ApoB) messenger RNA in infected cells causes a 70%
reduction in the secretion of both ApoB-100 and HCV. More importantly, we
demonstrate that the grapefruit flavonoid naringenin, previously shown to inhibit VLDL
secretion both in vivo and in vitro, inhibits the microsomal triglyceride transfer protein
activity as well as the transcription of 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase and acyl-coenzyme A:cholesterol acyltransferase 2 in infected cells.
Stimulation with naringenin reduces HCV secretion in infected cells by 80%. Moreover,
we find that naringenin is effective at concentrations that are an order of magnitude
below the toxic threshold in primary human hepatocytes and in mice.
2.2 Results
2.2.1 Huh7.5.1-Secreted HCV Is Bound to ApoB
Recent evidence suggests that HCV binds to low-density particles prior to virus egress
(3) and that viral secretion requires both ApoB expression and VLDL assembly to occur
(4). Therefore, HCV secreted by the JFH1/Huh7.5.1 full viral lifecycle model could
potentially be secreted while bound to VLDL. To determine if Huh7.5.1-produced HCV is
bound to VLDL, we immunoprecipitated the Huh7.5.1-conditioned medium against
human ApoB antibodies and detected bound HCV core protein in the eluted sample. The
results presented in Figure la demonstrate that HCV core protein is bound to ApoB-100
in our samples. HCV core could not be detected when the sample was precipitated
against irrelevant antibody (control) but was easily detected in the cell medium (JFH1).
2.2.2 HCV Secretion Mirrors That of VLDL
The interaction between HCV and ApoB suggests that the virus is be actively secreted by
the cells while bound to VLDL. However, the interaction between these particles might
also occur outside the cell. To determine if HCV is being actively secreted by the cells
while bound to VLDL, we studied viral secretion in response to oleate and insulin
stimulation, which have previously shown to oppositely modulate ApoB secretion in
culture (5). Figure lb shows ApoB, HCV core, and HCV-positive strand RNA secretion by
Huh7.5.1 cells infected with the JFH-1 virus. As expected, ApoB secretion is significantly
up-regulated by oleate (p=0.002) and down-regulated by insulin (p=0.007) in a dose-
dependent manner. Similarly, HCV core protein secretion is significantly up-regulated by
oleate (p=0.007) and down-regulated by insulin (p = 0.02) in a dose-dependent manner.
The secretion of HCV-positive strand RNA, measured by qRT-PCR, follows the same path.
However, intracellular levels of HCV RNA remained unchanged following both
treatments.
Brefeldin A is a commonly used toxin that disrupts communication between the
endoplasmic reticulum and the Golgi, inhibiting the active secretion of proteins (5-7).
Not surprisingly, the addition of brefeldin A (2.5 g/mL) blocked ApoB secretion
(p=0.0001). Interestingly, brefeldin A significantly inhibits the secretion of HCV core
protein (p=0.002) and HCV-positive strand RNA (p=0.007). To assess whether the
changes in HCV core protein and RNA secretion correlate with changes of viral infectivity
in the cell supernatant, we measured the ability of the secreted virus to infect naive
Huh7.5.1 cells. Figure 1c shows that the infectivity of the cell supernatant increased
following oleate stimulation, decreased because of insulin, and was strongly inhibited
following brefeldin A stimulation by 89% ± 10% (p=0.001). These results suggest that
HCV is being actively secreted by the cells, perhaps while bound to VLDL.
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Figure 1 (A) Immunoprecipitation of Huh7.5.1-secreted ApoB followed by anti-HCV core staining
(coimmunoprecipitation). (B) Cell culture secretion of ApoB, HCV-positive strand RNA, and HCV core
protein in JFH-1-infected Huh7.5.1 cells in response to oleate, insulin, and brefeldin A. The secretions of
ApoB, HCV RNA, and HCV core protein are significantly up-regulated by oleate and down-regulated by
insulin in a dose-dependent manner. Brefeldin A, which blocks Golgi-dependent secretion of proteins,
significantly inhibits the secretion of ApoB, HCV RNA, and HCV core. Cell viability for all conditions was
greater than 90%. (C) Infectivity of cell culture supernatant assessed by colony formation on naive
Huh7.5.1 cells: oleate (0.8 mM), insulin (500 U/L), brefeldin A (2.5[tg/mL), and naringenin (200pM).
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2.2.3 HCV Core Antigen Colocalizes with ApoB
Previously, HCV core protein was shown to associate with ApoAll (8) and lipid droplets
in HepG2 cells (9) overexpressing the core protein. Just recently, Huang et al. (4)
demonstrated that HCV core protein colocalizes with ApoB in a chromosomally
integrated cDNA model of HCV. To ascertain if HCV core protein associates with ApoB in
JFH-1 virus-infected Huh7.5.1 cells, we double-stained Huh7.5.1 cells 2 days post
infection by immunofluorescence for both viral and native proteins. Figure 2
demonstrates the colocalization of HCV's core and ApoB100 in infected cells. HCV core
protein associates with areas in the cytoplasm that are positive for ApoB100. However,
we note that although the proteins appear to be closely associated, we fail to find a
one-to-one correspondence between the viral and native proteins in our model of the
full viral lifecycle.
The association between ApoB100 and HCV core protein as well as previous data
suggests that HCV might be tagging along ApoB secretion. Therefore, silencing ApoB
production in the cell might decrease HCV secretion. Figure 2d demonstrates a 69%
6% decrease in ApoB secretion following transfection with SureSilencing shRNA (P =
0.0001). Interestingly, HCV core protein secretion was significantly decreased by 75%
4% at the same time (P = 0.0002). HCV-positive strand RNA secretion was also
significantly decreased by 69% ± 4% (P = 0.0015).
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Figure 2 - Double immunofluorescence staining of JFH-1-infected Huh7.5.1 cells. (A) Staining for HCV core
protein (red). (B) Staining for ApoB1OO (green). (C) Superpositioning of the images demonstrates that HCV
core protein associates with ApoBIO in the cytoplasm. (D) Relative secretion of ApoB, HCV-positive
strand RNA, and HCV core protein in JFH-1-infected Huh7.5.1 cells following silencing of ApoB100 mRNA
by SureSilencing shRNA transfection. **p<0.01.
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2.2.4 HCV Secretion Is Inhibited by Naringenin
Naringenin is a grapefruit flavonoid previously shown to reduce cholesterol levels both
in vivo (10-13) and in vitro (14-16). It is thought that naringenin inhibits ApoB secretion
by reducing the activity and expression of MTP and ACAT (14, 16). To assess if
naringenin inhibits HCV secretion in a similar manner, we cultured infected Huh7.5.1
cells in the presence of naringenin for 24 hours. Figure 3a demonstrates that naringenin
inhibits the secretion of HCV core (p=0.0001) and HCV-positive strand RNA (p=0.0006) in
a dose-dependent manner. At the concentration of 200pM, naringenin inhibited HCV
secretion by 80% ± 10%. Interestingly, intracellular levels of HCV-positive strand RNA
(Figure 3c) remained unchanged. To assess whether the naringenin-induced inhibition
of HCV core protein and RNA secretion correlated with changes of viral infectivity in the
cell supernatant, we measured the ability of the secreted virus to infect naive Huh7.5.1
cells. Figure 1c shows that the infectivity of the cell supernatant was strongly inhibited
following naringenin stimulation by 79% ± 10% (p=0.002).
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Figure 3 - (a) Inhibition of ApoB, HCV-positive strand RNA, and HCV core protein secretion by the
grapefruit flavonoid naringenin. Naringenin significantly inhibits the secretion of HCV core (p=0.0001) and
HCV-positive strand RNA (p=0.0006) in a dose-dependent manner. At the concentration of 200LM,
naringenin inhibited HCV secretion by 80% ± 10%. Cell viability for all conditions was greater than 90%.
**p<0.01. (b) Naringenin inhibits the activity of MTP in a dose-dependent manner. At the concentration of
200pM, MTP activity was reduced by 58% ± 8% (p=0.001). (c) Naringenin induces changes in hepatic gene
transcription measured by qRT-PCR. HMGR transcription was reduced by 57% + 3% (p=0.01), whereas the
transcription of ACAT2 was reduced by 55% + 7% (p=0.016). The mRNA levels of actin, MTP, and ACAT1
remained unchanged. Intracellular RNA levels of HCV core also remained unchanged during the 24 hours
of treatment. **p<0.02.
2.2.5 Naringenin Does Not Display Hepatic or In Vivo Toxicity
To assess the potential of naringenin-based treatment, we measured ApoB secretion in
primary human hepatocytes following 24 hours of stimulation with naringenin. Figure
4a demonstrates a dose-dependent decrease in ApoB secretion following naringenin
stimulation. At 200ptM naringenin, ApoB secretion was reduced by 60% ± 7% (p=0.007).
The viability of primary human hepatocytes exposed to increasing concentrations of
naringenin is shown in Figure 4b. Human hepatocyte viability was 81% ± 3% at 200IM
naringenin and was not judged to be statistically different than that of the control (78%
± 3%). Human hepatocyte viability dropped significantly only at naringenin
concentrations greater than 1000M.
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Figure 4 - (a) Naringenin stimulation inhibits ApoB secretion of primary human hepatocytes in a dose-
dependent manner. At 200 M naringenin, ApoB secretion was reduced by 60% ± 7% (p=0.007). (b)
Viability of freshly isolated human hepatocytes exposed to increasing concentrations of naringenin for 24
hours. Human hepatocyte viability was 81% ± 3% at 200RM naringenin and was not judged to be
statistically different than the control (77% ± 3%). Human hepatocyte viability dropped significantly only
at naringenin concentrations greater than 1000tM.
To further assess naringenin potential, we delivered naringenin by intraperitoneal
injection to 8-week-old male SCID mice at concentrations of 60, 300, and 1500 mg/kg
(approximately 200, 1000, and 5000 M). Animal survival was not affected by naringenin
at these doses. To discern if liver damage occurred, we measured levels of AST and ALT
in the animals' plasma 48 hours following injection. Figure 5a demonstrates that there
was no elevation of ALT levels under all conditions. AST levels appeared to increase but
remained under 100 U/L even at the highest dose. To assess naringenin's ability to
reduce circulating VLDL levels, we measured total triglyceride levels in animal plasma.
Figure 5b demonstrates a decrease in triglycerides following naringenin injection.
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Figure 5 - Animal survival and liver enzyme release following intraperitoneal (i.p.) injection of naringenin
into 8-week-old male SCID mice. Animals were injected with naringenin at 60, 300, and 1500 mg/kg of
body weight. Animals were sacrificed at 48 hours, at which time liver enzymes (AST and ALT) and total
triglycerides were analyzed in the animals' plasma. (a) Animal survival was monitored for several days
following injection and was not affected even at the highest dose (1500 mg/kg). The ALT level appeared
unchanged over all conditions, whereas AST was found to be slightly elevated at the highest dose. (b)
Total triglycerides analyzed in animal plasma 24 hours following injection decreased in response to
naringenin.
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2.3 Discussion
The recent development of the JFH-1 virus (17) in combination with the Huh7.5.1 cell
line (18) has allowed for the efficient infection of cells and the generation of large virus
titers in culture. This model allows for the identification of intercellular infectious HCV
particles with a higher density than that of their secreted counterparts (3), suggesting
the binding of HCV to low-density particles in the endoplasmic reticulum. Just recently,
Huang et al. (4) demonstrated that HCV assembled in ApoB and MTP enriched vesicles
and that the viral secretion was dependent on both ApoB expression and VLDL assembly
in a chromosomally integrated cDNA model of HCV secretion. As the association
between HCV and serum lipoproteins (VLDL and LDL) is well known (19), these results
strongly suggest that HCV might hitch a ride on the lipoprotein-cholesterol lifecycle. This
hypothesis is intriguing as it might explain the presence of HCV in intestinal cells, a
second site of lipoprotein production (20). In addition, it might explain HCV uptake by
LDL receptor (21, 22), scavenger receptor class B type I (23), and heparin sulfate (24).
Our results strongly support this hypothesis. We demonstrate that HCV produced by the
Huh7.5.1 cell line is bound to ApoB and that its secretion is inhibited by brefeldin A, a
metabolite of the fungus Eupenicillium brefeldianum, which blocks the communication
between the endoplasmic reticulum and the Golgi apparatus, effectively inhibiting
protein secretion (5-7). We also demonstrate that HCV secretion is up-regulated by the
fatty acid oleate and down-regulated by insulin, precisely mirroring ApoB secretion by
the cells (5). Moreover, silencing ApoB100 mRNA caused a significant and parallel
decrease in HCV core protein secretion. This ApoB-dependent HCV secretion pathway
suggests a novel therapeutic approach for the treatment of HCV infection.
The ability of naringenin, or its glycosylated form, to significantly reduce plasma
cholesterol levels has been demonstrated both in vivo (10-13) and in vitro (14-16). Our
results demonstrate that short-term (24-hour) stimulation of infected hepatocytes with
200[tM naringenin significantly inhibits HCV secretion by 80% ± 10% and the infectivity
of the titer by 79% ± 10%. At the same time, transcription of the viral RNA remains
unchanged. We suggest that this is due in part to the inhibition of MTP activity by 58% +
8% as well as the inhibition of HMGR and ACAT2 transcription. To further demonstrate
naringenin as a potential therapy, we show that the compound is nontoxic to freshly
isolated human hepatocytes up to concentrations greater than 1000RM. In addition, we
demonstrate that naringenin induced a 60% ± 7% decrease in ApoB secretion by primary
human hepatocytes.
The concept of supplementing HCV patients' diets with naringenin is appealing. A recent
clinical trial in hypercholesterolemic patients demonstrated that a low dose of naringin
(400 mg/day) lowered LDL levels by 17% (25). A similar cholesterol-lowering effect of
naringenin was demonstrated in rabbits (10, 11) and rats (26). However, it is worth
noting that the absorbance of naringenin through the intestinal wall is limited (less than
8%). Prior studies have suggested that the Medium Lethal Dose LD50 for naringenin is
>5000 mg/kg for rats by intragastric administration (27). Our results show that doses up
to 1500 mg/kg naringenin given by intraperitoneal injection to mice did not cause death
or a marked elevation of liver enzymes, suggesting that intravenous administration of
naringenin is in the realm of possibility.
The ability of the liver to regenerate in the context of the RNA-based lifecycle of HCV
allows for the potential clearance of the viral infection. It is thought that clearance
occurs in about 15-25% of HCV-infected patients. The possible reduction of HCV viral
load by inhibiting viral secretion could allow uninfected cells to regenerate, potentially
increasing the overall rate of viral clearance.
2.4 Materials and methods
Reagents and Antibodies
Fetal bovine serum (FBS), phosphate-buffered saline (PBS), Dulbecco's modified Eagle
medium (DMEM), penicillin, streptomycin, and trypsin-ethylene diamine tetraacetic acid
(EDTA) were obtained from Invitrogen Life Technologies (Carlsbad, CA). Lipoprotein-free
FBS was purchased from Biomedical Technologies (Stoughton, MA). Insulin was
obtained from Eli-Lilly (Indianapolis, IN). Oleate, naringenin, and brefeldin A were
purchased from Sigma-Aldrich Chemicals (St. Louis, MO). Immunofluorescence-grade
paraformaldehyde was purchased from Electron Microscope Sciences (Hatfield, PA).
OptiMEM I basal medium and Lipofectamine 2000 were purchased from Invitrogen Life
Technologies. The SureSilencing shRNA plasmid kit for human ApoB [green fluorescent
protein (GFP)] was purchased from SuperArray (Frederick, MD). An MTP fluorescent
activity kit was purchased from Roar Biomedical (New York, NY). Unless otherwise
noted, all other chemicals were purchased from Sigma-Aldrich Chemicals. For
immunoprecipitation, Protein A-Sepharose was purchased from Invitrogen, whereas
horseradish peroxidase-conjugated goat anti-mouse secondary was purchased from
Santa Cruz Biotech (Santa Cruz, CA). For immunofluorescence studies, normal donkey
serum and secondary F(ab')2 antibody fragments (multiple-labeling [ML] grade) were
obtained from Jackson Immunoresearch (Bar Harbor, ME). Mouse anti-HCV core antigen
(5 [tg/mL) was purchased from US Biological (Swampscott, MA). Goat anti-ApoB (10
Ig/mL) was purchased from R&D Systems, Inc. (Minneapolis, MN).
Cells and Viruses
The Huh7.5.1 human hepatoma cell line and a plasmid containing the JFH-1 genome
were kindly provided by Dr. Chisari (Scripps Research Institute, La Jolla, CA) and Dr.
Wakita (National Institute of Infectious Diseases, Tokyo, Japan), respectively. Huh7.5.1
cells were cultured in DMEM supplemented with 10% FBS, 200 units/mL penicillin, and
200 mg/mL streptomycin in a 5% CO2-humidified incubator at 370 C. In vitro transcribed
genomic JFH-1 RNA was delivered to cells by liposome-mediated transfection as
described by Zhong et al. (18) Infected Huh7.5.1 cells were passaged every 3 days and
used at passage <15. The presence of HCV in these cells and corresponding supernatants
were determined by quantitative, reverse-transcription, polymerase chain reaction
(qRT-PCR) and immunofluorescence staining. Primary human hepatocytes were
purchased from BD Biosciences (San Jose, CA) and cultured on a collagen-coated 12-well
plate in a C+H culture medium composed of DMEM supplemented with 10% heat-
inactivated FBS, 200 U/mL penicillin/streptomycin, 7.5 Rg/mL hydrocortisone, 20 ng/mL
epidermal growth factor (EGF), 14 ng/mL glucagons, and 0.5 U/mL insulin. The medium
was supplemented with 2% dimethyl sulfoxide for long-term culture of the primary cells.
HCV Secretion
HCV-infected Huh7.5.1 cells were plated on a 6-well plate at a density of 1x10 5 cells/cm 2
and cultured overnight in the standard medium. Prior to the beginning of the
experiment, the cells were washed 3 times with PBS and cultured with DMEM
containing 5% lipoprotein-free FBS. Oleate, insulin, naringenin, and brefeldin A were
added at this time as described in the text. Following 24 hours of incubation, the plate
was gently agitated to release mechanically bound particles, and the medium was
collected, filtered to remove cellular debris, and stored at -800C for further analysis. The
attached cells were washed 3 times with PBS, harvested, pelleted, and stored at -80"C
for further analysis.
Coimmunoprecipitation
The binding of Huh7.5.1-secreted JFH1 particles to ApoB was assessed with
coimmunoprecipitation. Anti-human ApoB-100 antibody (5Rg) was bound to 100RL of
Protein A-Sepharose on ice. Three milliliters of the JFH1-infected Huh7.5.1 conditioned
medium (1x106 cells/mL) was added to the mixture, which was subsequently rotated for
4 hours at 40C. The sample was spun down at 10,000g in a microcentrifuge and washed
3 times with 50 mM trishydroxymethylaminomethane (Tris)-HCI (pH 7.5) containing 5
mM EDTA. Finally, the sample was eluted in 100 tL of 10 mM Tris-HCI (pH 8.5)
containing sodium dodecyl sulfate. The protein concentration in the eluted buffer was
quantified as described later, and 20 xg of protein was loaded onto a 7.5% Tris-HCL
resolving gel. Resolved proteins were transferred to a polyvinylidene fluoride membrane
and stained against HCV core (0.5[tg/mL).
HCV Infectivity
The infectivity of the secreted HCV particles was measured as previously described (18).
Naive Huh7.5.1 cells were grown to 80% confluence and exposed to cell culture
supernatants diluted 10-fold in the culture medium. Following 1 hour of incubation at
370C, the medium was replaced, and the cells were cultured for 3 additional days. Levels
of HCV infection were determined by immunofluorescence staining for HCV core
protein. The viral titer is expressed as focus forming units per milliliter of supernatant.
Human ApoB Enzyme-Linked Immunosorbent Assay (ELISA)
Huh7.5.1-secreted and primary human hepatocyte-secreted ApoB was detected in the
medium with the ALerCHEK, Inc. (Portland, ME), total human ApoB ELISA kit. The
medium was diluted 1:10 with the specimen diluent, and the assay was carried out
according to the manufacturer's directions.
HCV Core Antigen ELISA
Huh7.5.1-secreted HCV core antigen was detected in the medium with the Wako
Chemicals (Cambridge, MA) ORTHO HCV antigen ELISA kit. The medium was used as is,
and the assay was carried out according to the manufacturer's directions.
Total Protein Assay
The total protein content of the cells was measured with the Bio-Rad Laboratories
(Hercules, CA) protein assay based on the Bardford method. Briefly, a cell pellet was
lysed in 350 tL of 0.1% Triton X-100, and 5 tL samples were loaded onto a 96-well plate
and incubated for 15 minutes with 250tL of Coomassie Blue reagent at room
temperature. Absorbance was measured at 595 nm and compared to a bovine serum
albumin standard.
Quantitative, Real-Time, Reverse-Transcription Polymerase Chain Reaction (PCR)
Virus samples collected in each experiment were filtered with a 0.45 tm filter, and a
volume of 100tL for each sample was heated at 950C for 45 minutes. The reverse-
transcription reaction step was performed on a Mastercycler epgradientS (Eppendorf)
instrument using Omniscript and Sensiscript RT kits (Qiagen). Real-time PCR was
performed on a Light Cycler LC-24 (Idaho Technology) using SuperScript Ill Platinum
CellsDirect Two-Step qRT-PCR kits (Invitrogen). For the reverse-transcription step, 2 tL of
a sample without RNA extraction was used. For real-time PCR, 1 tL of the reverse-
transcription reactions was used. All reactions were performed according to the
manufacturer's instructions with the primers detailed in Table 1.
Gene Primer
HCV 5 untranslated region
MTP
ACAT1
HMGR
Actin
ACAT2
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
5'-GCAGAAAGCGTCTAGCCATGGCGT-3'
5'-CTCGCAAGCACCCTATCAGGCAGT-3'
5'-GAGGTTTCTCTATGCCTGTGGATTT-3'
5'-CCCAGGATTAACTTCTTAGCTTCCA-3'
5'-CAATACAATGGTGGGTGAAGAGAAG-3'
5'-AAAATCTTTCCTTGTTCTGGAGGTG-3'
5'-GACCCCTTTGCTTAGATGAAAAAGA-3'
5'-GGACTGGAAACGGATATAAAGGTTG-3'
5'-GTCGTACCACTGGCATTGTG-3'
5'-CTCTCAGCTGTGGTGGTGAA-3'
5'-CATGCGGGAGGCTATACAAT-3'
5'-GTAGATGGTGCGGAAATGCT-3
Table 1- Primers used in qRT-PCR experiments.
Cellular Viability
The viability of both Huh7.5.1 cells and primary human hepatocytes was studied with
Thermo Fisher Scientific (Waltham, MA) Infinity aspartate aminotransferase (AST) liquid
reagent. Medium samples (15ptl/well) were loaded onto a 96-well plate in triplicates
and mixed with 150 tL of the AST liquid reagent. Absorbance decay was measured at the
wavelength of 340 nm with 15-second intervals in a Bio-Rad Benchmark Plus
spectrophotometer. Values were normalized to the total amount of AST available per
culture, which was determined by total cell lysis induced by 1% Triton X-100 for 20
minutes at room temperature. Cell viability for all conditions reported in the Results
section was greater than 90%.
MTP Activity Assay
MTP activity was analyzed with an MTP assay kit as previously described (28). The assay
is based on a transfer of a fluorescent signal between donor and acceptor particles due
to MTP activity. Briefly, confluent Huh7.5.1 cells were stimulated with naringenin or a
carrier control for 24 hours and were then washed with ice-cold PBS and scraped off the
dish with a cell scraper. Samples were homogenized by sonication (3 x 5 seconds) in a
buffer containing protease inhibitors. The MTP assay was performed by the incubation
of 50g of cellular protein with 10 tL of donor and acceptor solutions in 250 L of total
buffer (15 mM Tris, pH 7.4; 40 mM NaCl; 1 mM EDTA). The increase in the fluorescent
signal was measured over 12 hours at 370C at the excitation wavelength of 465 nm and
emission wavelength of 538 nm.
Animal Studies
Male SCID mice (8 weeks old, 20-25 g) were obtained from Charles River Laboratories
(Wilmington, MA). Animals were treated in accordance with National Institutes of
Health guidelines and the Massachusetts General Hospital Subcommittee on Research
Animal Care. The mice were allowed free access to laboratory chow and water ad
labium. Naringenin was dissolved in 0.5% Tween 20 diluted in saline and given by
intraperitoneal injection. Two days following the treatment, animals were sacrificed,
and blood was withdrawn by cardiac puncture. AST and alanine aminotransferase (ALT)
enzyme levels were assessed as described previously. Total triglycerides were measured
with a kit purchased from Sigma-Aldrich Chemicals according to the manufacturer's
instructions.
Silencing ApoB mRNA
HCV-infected Huh7.5.1 cells were plated in T-25 tissue culture flasks at a density of
1x105 cells/cm 2 and cultured overnight in the standard medium. Prior to silencing, the
cells were washed 3 times with PBS, and the medium was replaced with OptiMEM basal
medium. SureSilencing shRNA (GFP) plasmids against human ApoB100 as well as shRNA
plasmid control (500 ng/mL) were combined with Lipofectamine 2000 in OptiMEM and
incubated with the cells overnight. SureSilencing shRNA plasmids code for GFP, which
was used to sort the transfected Huh7.5.1 cells with FACSAria (BD Biosciences) located
at the Partners AIDS Research Center. Transfected cells (10% of the total population)
were sorted directly into a 12-well plate and allowed to adhere overnight. The culture
medium was conditioned by the transfected cells for 24 hours and analyzed as described
previously.
Immunofluorescence Microscopy
Huh7.5.1 cells were washed 3 times with PBS and fixed in 4% electron microscopy-grade
paraformaldehyde for 10 minutes at room temperature. Slides were then washed with
PBS and incubated in 100 mmol/L glycine for 15 minutes to saturate reactive groups.
Samples were permeabilized for 15 minutes with 0.1% Triton X-100, blocked for 30
minutes with 1% bovine serum albumin and 5% donkey serum at room temperature,
and stained with primary antibodies overnight at 40C. After additional washes with PBS,
samples were stained with fluorescently tagged secondary antibodies for 45 minutes at
room temperature.
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3 Naringenin Inhibits the Assembly and Long-Term Production of
Infectious Hepatitis C Virus Particles Through a PPAR-Mediated
Mechanism
3.1 Introduction
Hepatitis C virus (HCV) infection affects around 2% of the world population and is the leading
cause of chronic liver disease worldwide (1). The current standard of care, a combination
treatment of pegylated-interferon c and ribavirin, is effective in only 50% of the patients, is
poorly tolerated, and is associated with significant side effects and the emergence of resistant
strains (2). Therefore, there is a pressing need for the development of alternative treatment
strategies to combat HCV infection. Recently, our group and others demonstrated that the HCV
lifecycle is critically dependent on host lipid metabolism (3-6). We have shown that HCV
production is metabolically modulated and suggested that the grapefruit flavonoid naringenin
could prove to be an effective inhibitor of HCV production (3). Here we demonstrate that
naringenin dose-dependently inhibits HCV production without affecting intracellular levels of
the viral RNA or protein. We further demonstrate that naringenin blocks the assembly of
intracellular infectious viral particles, upstream of viral egress. We show that this antiviral effect
is mediated by the inhibition of MTP coupled with the activation of the nuclear receptors
PPARct and PPARy, leading to a decrease in VLDL production without causing lipid accumulation
in the cells. Finally, long-term treatment with naringenin leads to a rapid 1.4 log reduction in
secreted HCV, not significantly different than 1000 l.U. of interferon. However, during the
washout period, HCV levels returned to normal, consistent with our proposed mechanism of
action. The data strongly supports further investigation of naringenin in the management and
care of HCV infection. The combination of naringenin with STAT-C agents could potentially bring
a rapid reduction in HCV levels during the early treatment phase, which has been associated
with a better long-term outcome (7).
3.2 Results
3.2.1 Naringenin inhibits the production of ApoB and HCV
Recently, our group and others demonstrated that HCV secretion in dependent on the assembly
and secretion of ApoB through an MTP mediated mechanism (3, 4). We have recently
demonstrated that naringenin, a grapefruit flavonoid with demonstrated anti-inflammatory,
and hypolipidemic properties blocks the production of HCV in JFH1-infected Huh7.5.1 cells (3)
(8). To further characterize naringenin's antiviral activity we treated JFH1-infected Huh7.5.1
cells with increasing concentrations of naringenin for 24 hours. Figure la shows that naringenin
led to a dose-dependent decrease in the secretion of ApoB and viral RNA, with an EC50 of 109
IM. Maximal inhibition of secretion of both ApoB and HCV RNA was 74±4% at a concentration
of 200 pM. Interestingly, no change in intracellular HCV RNA was noted up to 200 tM
suggesting the compound does not affect viral replication. To further explore the effects of
naringenin on viral components, infected cells were treated with 200 IM naringenin for 24
hours. Treatment did not lead to an accumulation of viral core protein or viral RNA in cells
(Figure 1b).
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Figure 1 - (a) Naringenin dose-dependently inhibits ApoB-100, HCV RNA, and HCV core protein secretion from
JFH1-infected Huh7.5.1 cells. ApoB and viral RNA were reduced by 80% and 72%, respectively. Viral RNA did not
accumulate in cells. (b) Chronically infected cells were treated with naringenin. Naringenin treatment decreased
the secretion of virus into the media, but did not change the amount of viral RNA or core protein inside cells.
Values are normalized to untreated controls.
-0
cu
>
0 L)
"i;
800
6
3.2.2 Naringenin blocks the assembly of HCV infectious particles
We next wished to determine whether naringenin blocks the assembly of HCV prior to viral
egress. Cells were first treated with 0.1 pg/mL brefeldin A (BFA), a toxin known to disrupt Golgi-
dependent export (3, 4). BFA treatment had previously shown to cause the accumulation of
intracellular infectious HCV particles in Huh7.5.1 infected cells (4). Co-treatment of cells with
BFA and the MTP-inhibitor, BMS-200150, had previously been shown to block the accumulation
of intracellular infectious HCV particles, suggesting MTP is required for HCV assembly (4). As
naringenin was previously shown to inhibit MTP activity, we explored if the compounds
similarly blocks HCV assembly.
JFH1-infected Huh7.5.1 cells were treated with 0.1 tg/mL BFA and co-treated for 5 hours with
10 pM BMS-200150 or 200 iM naringenin. The production of extracellular infectious particles
(Figure 2b) was significantly reduced when cells were treated with either BMS-200150 or
naringenin (45% and 68%, respectively, p<0.02) and abolished entirely when cells were treated
with BFA (p<0.001). Expectedly, BFA treatment which blocked the production of extracellular
infectious particles, lead to the accumulation of infectious HCV particles within the cells (Figure
2a). Co-treatment with BMS-200150 decreased the accumulation of infectious particles by 46%
(p<0.05) compared to BFA-only controls. Importantly, co-treatment with naringenin decreased
the accumulation of infectious particles by 42% (p<0.05) compared to BFA-only controls (Figure
2a) suggesting the flavonoid inhibits the assembly of HCV lipo-viral particles (9).
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Figure 2 - Naringenin (NN) blocks the assembly intracellular infectious virus particles. (a) Infected cells were
treated with 0.1 Ig/mL BFA and co-treated with either 10 iM BMS-200150, a known MTP inhibitor (MTPi), or with
200 pM naringenin. Cells were lysed by freeze-thaw and virus-containing supernatant was used in an infectivity
titer assay. BFA treatment led to accumulation of infectious virus in cells. BMS-200150 treatment prevented the
accumulation of infectious virus in cells, leading to a 46% (p<0.05) decrease in infectious particle accumulation.
Naringenin had a similar effect to that of the MTP inhibitor, leading to a 42% (p<0.05) decrease in infectious
particle accumulation. (b) Extracellular infectivity was similarly inhibited by both BMS-200150 and naringenin, by
45% and 68%, respectively (p<0.02). Conducted by our collaborator, Dr. Steve Polyak of University of Washington.
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3.2.3 Naringenin inhibits MTP activity while inducing PPAR activity
Naringenin has been previously shown to inhibit MTP, a critical enzyme in VLDL assembly, in
HepG2 cells (10, 11). More recently, the compound was shown to induce PPRE activity in U-20S
cells (12). To explore if naringenin inhibits MTP activity in infected and uninfected Huh7.5.1
cells, cells were treated with 200 ptM of naringenin for 24 hours. Cells were subsequently lysed
and assayed for MTP activity as previously described (3). Naringenin inhibited MTP activity by
58%±4% in infected cells and 67%±12% in uninfected cells compared to DMSO-treated controls
(Figure 3a). Previous reports have indicated that MTP inhibition can lead to lipid accumulation
and steatosis. To test if naringenin leads to lipid accumulation, primary rat hepatocytes were
treated with naringenin for 24 hours and cellular lipids were quantified by Oil-Red-O staining as
previously described (13). Oil-Red-O staining showed no significant accumulation of lipids in
cells treated with 200 or 400 tM naringenin (Figure 3b).
Cellular lipid metabolism is controlled by several nuclear receptors, members of a family of
ligand-activated transcription factors (14). Activation of PPARc specifically, has been shown to
induce p-oxidation and a reduction in lipogenesis and VLDL secretion (15). Such activation could
explain the lack of lipid accumulation. To examine if naringenin induces PPAR activation we
used the HG5LN-PPARa reporter cell line (16). In this cell line, the PPARc ligand binding domain
(LBD) is fused to a GAL4 DNA binding domain. Activation of PPARa-LBD allows GAL4 to bind its
UAS response element transcribing luciferase. Figure 3c shows that naringenin treatment
enhanced the activity of the PPARa-LBD 2.4-fold (p<0.001).
To examine if the activation PPARa-LBD in the reporter cell line correlates with PPRE activity in
JFH1-infected Huh7.5.1 cells, we transfected infected cells with the pAOx(X2)luc reporter
plasmid which contains two tandem repeats of the AOX PPAR response element (PPRE)
upstream of the firefly luciferase reporter gene (17). Renilla luciferase expression was used as
control. As shown in Figure 3d, naringenin led to a dose-dependent increase in PPRE activity,
reaching 23% ± 7% (p=0.015) compared to DMSO-treated control. To verify that PPARa
activation could indeed reduce ApoB and virus production in our system, we treated Huh7.5.1
cells with classical PPARa agonist, WY-14,643. Cells treated with the agonist produced only 67%
and 37% of the amount of ApoB and HCV RNA, respectively, compared to DMSO-treated
controls, a reduction similar to that observed in naringenin-treated cells (Figure 3E).
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Figure 3. Naringenin (NN) enhances PPAR and inhibits MTP activity in infected cells. (a) Naringenin decreased MTP
activity by 33% and 42% for uninfected and infected cells, respectively, without leading to accumulation of lipids in
cells (b). (c) HG5LN-PPARa cells were treated with varying amounts of naringenin. Naringenin enhanced PPARa-
LBD activity by 140% ± 5% (p<0.001) Conducted by our collaborator, Dr. Patrick Balaguer of Univ Montpellier I,
France. (d) Chronically infected cells were co-transfected with pAOx(X2)Luc and pRL-TK overnight and then treated
with naringenin for 24 hours. Naringenin dose-dependently enhanced PPRE activity by up to 24% ± 7% (p=0.015).
(e) Cells were treated with either 2001AM naringenin (NN) or 10LIM WY14,643 (WY). Both treatments led to similar
decreases in secreted ApoB and viral RNA.
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3.2.4 Long-term inhibition of HCV production
Given our observations that 24-hour treatment with naringenin significantly decreases viral
secretion, we were interested in exploring the flavonoid's effect on viral production over a
period of several days. We therefore treated chronically infected Huh7.5.1 cells with 200pM
naringenin over a course of 4 days (treatment). As a positive control, cells were treated with
1000 i.u of IFNa, a concentration previously shown to abolish viral production (18). On days 5-
7, treatment was removed from all cells (washout).
As expected, our results showed that ApoB secretion was decreased by naringenin treatment
(86%±1%, p<0.01), but not by IFNa that showed a 16%±3% increase. Importantly, naringenin
treatment caused a rapid 1.2 log reduction in HCV RNA and a 60% reduction in HCV core
(p<0.05). This inhibition in HCV production was similar to IFNa which showed a maximal 1.7 log
reduction in HCV RNA and a 70% reduction in HCV Core (Figure 4). Interestingly, during the
washout period, HCV levels in naringenin treated cells returned to normal suggesting that the
compound did not affect viral replication.
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Figure 4 - Naringenin causes a rapid inhibition of HCV production during long-term treatment. Cells were treated
for 4 days with 200 pM naringenin or 1000 iW IFNa, culture media was replaced daily. During the 3 day washout
period, all wells were treated with media without treatment. (a) Viral RNA release into media decreased during
treatment, down to 6% with naringenin and 2% with IFNat compared to controls. During washout phase,
naringenin-treated samples contained RNA levels similar to controls, suggesting viral replication was unchanged.
(b) HCV core levels in media decreased during treatment for naringenin and IFNa. For naringenin-treated cells on
days 4, core in the media was reduced to 40%±26%. Core accumulation was partly restored during the last day of
washout in both naringenin and IFNa-treated samples 78% ±17%, 82% ±20%, respectively. C) ApoB secretion
declined during treatment with naringenin. On days 4, ApoB secretion in naringenin-treated cells decreased to
13%±1%.
3.3 Discussion
HCV is a global public health problem affecting close to 3% of the world population. The current
standard of care consists of pegylated IFNax and ribavirin. Despite the high incidence of adverse
effects, this combination therapy is only effective in approximately half of the patients, and is
associated with the emergence of resistant strains (19, 20). While protease and polymerase
inhibitors developed in the context of STAT-C are showing a remarkable potential, similar
indications of resistant strains have already been reported in clinical trials. A complimentary
approach is to target a host pathway, such as VLDL assembly, on which the virus depends. HCV
would require numerous mutations and a significant alteration of its lifecycle to escape,
essentially becoming a different virus.
HCV is a positive-strand RNA virus, a member of the Flaviviridae family. The viral life cycle
begins upon entry into the host cell. The process of cell entry has yet to be clarified completely,
but may involve several cell-surface receptors, including the LDL receptor (LDLR) (21, 22).
Following entry, viral proteins are translated and accumulate in the cellular ER, inducing
morphological changes in the cell with the formation of a membranous web, where viral
replication has been reported to occur in ER-associated lipid droplets (23-26). Viral assembly is
thought to occur in the ER, where the virus attaches to either nascent or mature VLDL particles
(27, 28). Finally, the virus is exported out of the cell in a Golgi-dependent manner (Figure 5) (4).
Figure 5 - Lipid metabolism affects the HCV viral lifecycle. The availability of lipids, including triglycerides and
cholesterol, in the cell are essential for several steps in the viral lifecycle. Viral replication complexes are known to
associate with lipid droplets, and geranylgeranylation has been shown to be crucial for viral replication. Our group
and others have demonstrated the dependence of infectious particle assembly on the assembly and export of VLDL
from cells. Decreasing lipid production and inhibition of VLDL assembly in the ER are potential new approaches to
combating HCV infection. ACAT - acyl-CoA cholesteryl acyl transferase, MTP - microsomal triglyceride transfer
protein, VLDL - very low-density lipoprotein.
The link between the virus and lipid metabolism has been suggested by both observational and
experimental studies (29). The viral life cycle depends heavily on lipid metabolism, and both we
and others have shown that HCV replication is inhibited by statins and enhanced by the
addition of fatty acids (30, 31). Recently, Gastaminza et al. demonstrated the existence of high
density intracellular HCV infected particles suggesting the virus binds to low density particles in
the ER (28). Using a similar system, Huang et al. demonstrated that HCV assembled in vesicles
enriched in ApoB, ApoE, and MTP the main components required for VLDL assembly (27).
Lastly, our group and others demonstrated that HCV is actively secreted while bound to (VLDL)
(3, 4) and that its production can be metabolically modulated.
Our group has previously suggested that naringenin, a grapefruit flavonoid aglycone, could be
effective in inhibiting HCV production (3). Naringenin has been shown to possess antioxidative
and normolipidemic effects both in vitro and in vivo (8). The flavonoid has been reported to be
an MTP and ACAT inhibitor (29), and a regulator of cytochrome P4503A and 4A activity (30, 31).
In this study, we first showed that naringenin induced a dose-dependent inhibition of HCV RNA
and core protein secretion, down to 28% of untreated controls (Figure 1). The reduction in viral
RNA and protein production correlated with inhibition of HCV infectivity (Figure 2). On the
other hand, intracellular HCV RNA and protein levels showed no change in response to
naringenin treatment, suggesting naringenin was inhibiting a step downstream of viral
replication. Nonetheless, given the reduction in viral secretion, the lack of intracellular viral
RNA and protein accumulation may suggest a concurrent inhibition of viral replication or
enhanced viral degradation.
Assembly of infectious HCV particles has been previously demonstrated to be dependent on
MTP activity, and enzyme critical to VLDL assembly. The accumulation of infectious viral
particles in cells treated with BFA, a toxin which disrupts the Golgi network (32, 33), is
consistent with our own findings (3) and the observations of Chisari and coworkers (4). Here we
showed that naringenin, like MTP inhibitor BMS-200150, blocks the accumulation of infectious
particles in BFA-treated cells up to 42% (p<0.05) suggesting that the flavonoid blocks the
assembly of infectious viral particles. Consistent with this observation, we showed naringenin
inhibited MTP activity by 58%±4% in infected cells and 67%±12% in uninfected cells, consistent
with the observations of Huff and colleagues in HepG2 cells (10). In a recent clinical study
Cuchel and colleagues showed that while the MTP inhibitor BMS-201038 (now AEGR-733)
lowered LDL values, it was associated with steatosis and elevated ALT levels, leading to an early
termination of the study (34). To test if naringenin leads to a similar level of lipid accumulation,
cellular lipids were quantified following naringenin treatment. We show there was no
significant accumulation of lipids in cells treated with 200 or 400 tM naringenin (Figure 3b).
Our observations and those of other groups' regarding naringenin's ability to modulate the
expression of genes important in fatty acid oxidation, led us to examine the effects of
naringenin on the nuclear receptor PPARc. We demonstrate that naringenin has a direct effect
on PPARc ligand binding domain in the HG5LN-PPARa reporter cell line (16). Consistently,
naringenin showed a dose-dependent increase in PPRE activity in JFH1-infected Huh7.5.1 cells.
These results are consistent with recent observations of Liu et al. in U-2OS osteosarcoma cells
(12). Furthermore, Huh7.5.1 cells chronically infected with HCV treated with the PPARca agonist,
WY 16,463, showed a 67% decrease in ApoB secretion and a 37% decrease in HCV RNA
secretion (Figure 3d), supporting the hypothesis that PPARa induction contributes to
narigenin's inhibition of HCV production in hepatocytes.
Finally, we wished to demonstrate that naringenin could inhibit viral accumulation in media
over a period of several days (Figure 4). As expected, naringenin reduced the secretion of ApoB
by 86%. This effect was not observed in IFNa-treated cells. When media was examined for viral
core and RNA content, both naringenin and IFNa significantly reduced the secretion of HCV
RNA by 1.2 and 1.7 log, respectively. Importantly, naringenin's effect on viral secretion was
reversible, as viral secretion rebounded during washout, consistent with a mechanism of action
that does not eliminate intracellular replication of the virus.
Our results suggest that naringenin blocks the assembly of infectious HCV particles. The tight
link between HCV and VLDL assembly, described as lipo-viral particles, suggests a new approach
for combating the virus. We expect that targeting host metabolism rather than viral structural
elements will decrease the development of resistant strains. The application of naringenin or
other PPAR alpha agonists with STAT-C agents could bring a rapid reduction in HCV levels during
the early treatment phase, which has been associated with a better long-term outcome. Our
work strongly supports further investigation of naringenin in the management of HCV
infections.
3.4 Methods
Reagents
Lipoprotein-free FBS was purchased from Biomedical Technologies (Stoughton, MA).
Naringenin, WY14,643, Brefeldin A (BFA), and Oil-Red-O were purchased from Sigma-Aldrich
Chemicals (St. Louis, MO). Ciglitazone was purchased from Cayman Chemical (Ann Arbor, MI).
Immunofluorescence-grade paraformaldehyde was purchased from Electron Microscope
Sciences (Hatfield, PA). All other chemicals were purchased from Invitrogen Life Technologies
(Carlsbad, CA) unless otherwise noted. An MTP fluorescent activity kit was purchased from Roar
Biomedical (New York, NY). Unless otherwise noted, all other chemicals were purchased from
Sigma-Aldrich Chemicals. BMS-200150, a small molecule inhibitor of MTP was synthesized as
described (35), and solubilized in DMSO. The compound was provided by Pablo Gastaminza and
Francis Chisari.
Cell Culture and Viruses
The Huh7.5.1 human hepatoma cell line and a plasmid containing the JFH-1 genome were
kindly provided by Dr. Chisari (Scripps Research Institute, La Jolla, CA) and Dr. Wakita (National
Institute of Infectious Diseases, Tokyo, Japan), respectively. Huh7.5.1 cells were cultured in
DMEM supplemented with 10% FBS, 200 units/mL penicillin, and 200 mg/mL streptomycin in a
5% C02-humidified incubator at 370C. In vitro transcribed genomic JFH-1 RNA was delivered to
cells by liposome-mediated transfection as described by Zhong et al. (36). Infected Huh7.5.1
cells were passaged every 3 days and used at passage <15.
HCV Secretion
HCV-infected Huh7.5.1 cells were plated on a 6-well plate at a density of 1x10 5 cells/cm 2 and
cultured overnight in the standard medium. Prior to the beginning of the experiment, the cells
were washed 3 times with PBS and cultured with DMEM containing 5% lipoprotein-free FBS.
Naringenin was added at this time as described in the text. Following 24 hours of incubation,
the plate was gently agitated to release mechanically bound particles, and the medium was
collected, filtered to remove cellular debris, and stored at -80*C for further analysis. The
attached cells were washed 3 times with PBS, harvested, pelleted, and stored at -80*C for
further analysis.
Hepatocyte Isolation and Culture
Rat hepatocytes were harvested from adult female Lewis rats (Charles River Laboratories,
Boston, MA) weighing 150-200 g by way of a two-step in situ collagenase perfusion technique
modified by Dunn et al. (37). Hepatocyte viability after the harvest was greater than 90% based
on trypan blue exclusion. All animals were treated in accordance with National Research
Council guidelines, and the study was approved by the Subcommittee on Research Animal Care
at Massachusetts General Hospital. Hepatocyte purity was greater than 95%.
Hepatocytes were seeded directly on 6-well, collagen gel-coated plates at a density of 100,000
cells/cm2. Culture medium consisted of Hepatocyte Culture Medium (HCM) supplemented with
SingleQuots (Lonza, Walkersville, MD), and cultures were maintained in a 10% C02-humidified
incubator at 37"C.
Intracellular and Extracellular HCV Infectivity
The infectivity of HCV particles was measured as previously described (3). Briefly, naive
Huh7.5.1 cells were grown to 80% confluence and exposed to cell culture supernatants diluted
10-fold in the culture medium. Following 1 hour of incubation at 370C, the medium was
replaced, and the cells were cultured for 3 additional days. Levels of HCV infection were
determined by immunofluorescence staining for HCV core protein. The viral titer is expressed
as focus forming units (FFU) per milliliter of supernatant. To evaluate infectivity of intracellular
particles, cells were scraped into PBS and lysed by freeze-thawing as previously described (4),
diluted and used to assess infectivity as above.
GAL4-PPAR activation assays
PPAR activation was examined as previously described using the HGLN5 PPARc and PPARy cell
line (16). Briefly, HGLN5 cells were seeded at a density of 100,000 cells/cm2, test compounds
were added 8 hours later and incubated for 16 hours. Following treatment, cells were washed
with PBS and lysed in 25 mM Tris buffer (pH 7.8). Protein concentration was calculated using
the Bradford assay and used to normalize the luciferase activity. Finally, activation of PPARa
and PPARy reporters is presented as percent of maximal activation by the known agonists
GW7647 and BRL49653, respectively.
PPRE activation in JFH1-infected Huh7.5.1 cells
The pAOx(X2)luc plasmid which contains two tandem repeats of the AOX PPAR response
element (PPRE) upstream of the firefly luciferase reporter gene (17) was a kind gift of Dr. John
P. Capone (McMaster University, Canada). The pRL-TK plasmid containing the renilla luciferase
reporter under the control of a constitutive thymidine kinase promoter was purchased from
Promega Corporation (Madison, WI). JFH1-infected Huh7.5.1 cells were transiently transfected
with the pAOx(X2)luc and pRL-TK plasmids using Lipofectamine 2000 according to
manufacturer's directions. Following 24 hours incubation with naringenin, cells were lysed and
assayed using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to
the manufacturer's instructions. All measurements were done in triplicate and data are shown
as values normalized to renilla luciferase internal controls.
Human ApoB Enzyme-Linked Immunosorbent Assay (ELISA)
Huh7.5.1-secreted ApoB-100 was detected in the medium with the ALerCHEK, Inc. (Portland,
ME), total human ApoB-100 ELISA kit. The medium was diluted 1:10 with the specimen diluent,
and the assay was carried out according to the manufacturer's directions.
HCV Core ELISA
Huh7.5.1-secreted HCV core antigen was detected in the medium with the Wako Chemicals
(Cambridge, MA) ORTHO HCV antigen ELISA kit. The medium was used as is, and the assay was
carried out according to the manufacturer's directions.
MTP Activity Assay
MTP activity was measured using a commercially available fluorescence assay using a
commercial kit (Roar Biomedical, Inc., New York, NY). Huh7.5.1 cells were treated with
compounds added in fresh media as described above. After 24 hours, cells were scraped into
PBS on ice, centrifuged at 600g for 3min at 40 C to pellet the cells, and resuspended in
manufacturer homogenization buffer supplemented with protease inhibitor cocktail (Thermo
Scientific). Cell suspensions were then sonicated on ice 3 times for 3 seconds each. 100 tg cell
lysates were combined with 10 tL of donor and acceptor particles in 220 tL assay buffer, and
incubated at 37'C. Increase in fluorescence was measured using spectra MAX Gemini plate
reader with excitation of 465 nm and emission of 538 nm, with 530 nm cutoff. Finally, MTP
activity was normalized to sample protein content.
Quantitative, Real-Time, Reverse-Transcription Polymerase Chain Reaction (qRT-PCR)
Virus samples were purified using a QlAamp Viral RNA Mini Kit (Qiagen, Valencia, CA). The
reverse-transcription reaction step was performed on a Mastercycler epgradientS (Eppendorf)
instrument using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA). Real-time PCR was performed on a MyiQ Real-Time PCR Detection System using
iScript One-Step RT-PCR Kit With SYBR Green (Bio-Rad, Hercules, CA), according to the
manufacturers' instructions. HCV detection primers used in qRT-PCR were Forward 5'-
GGGAAGACTGGGTCCTTTCTTGGAT-3' and Reverse 5'- CGACGGTTGGTGTTTCTTTTGGTTT-3'
(Integrated DNA Technologies, Coralville, IA).
Lipid Measurements
Intracellular lipids were measured by Oil-Red-O staining. Cells were washed with PBS and fixed
in 10% pH-buffered formalin for 10 minutes, washed in 60% isoprpanol and dried for 15
minutes. Oil-Red-O working solution was added to cells and incubated at room temperature for
10 minutes. Cells were extensively washed visually inspected. Finally, intracellular Oil-Red-O
was eluted from cells by incubation in 100% isopropanol for 10 minutes, and quantified at
510nm.
Long-term Treatments
JFH1-infected Huh7.5.1 cells were grown over a course of 7 days in OptiMEM culture medium.
Media was collected every 24 hours and stored at -80*c for analysis. On Days 1-4 ("treatment"),
media contained 200lpM naringenin, 1000U/mL IFNa, or DMSO. On Days 5-7 ("washout"), all
wells were cultured in standard media without treatment.
Statistics
Data are expressed as the mean - standard deviation. Statistical significance was determined
by a one-tailed Student's t-test. A P-value of 0.05 was used for statistical significance.
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4 Naringenin is a PPARa and PPARy agonist and inhibits LXRa
4.1 Introduction
Dysregulation of lipid and carbohydrate homeostasis has been implicated in multiple disease
processes, such as atherogenesis, insulin resistance, and hypermetabolism (2, 3). Naringenin
has been recently suggested as a potential normolipidemic agent: in a recent clinical trial,
naringenin was shown to reduce circulating levels of low-density lipoprotein (LDL) by 17% in
hypercholesterolemic patients (7). Similarly, the cholesterol-lowering effects of naringenin have
been demonstrated in rabbits (8, 9) and rats (10).
Naringenin's in vitro ability to reduce cellular secretion of very-low density lipoprotein (VLDL)
and LDL (11, 12) through the inhibition of ACAT2 (11) and MTP (13, 14), along with its inhibition
of HMG CoA reductase (HMGR) and activation of enzymes important in fatty acid oxidation
such as CYP4A1 (15) suggest that the flavonoid may be targeting transcriptional regulation of
metabolism through nuclear receptors (NRs), a family of ligand-activated transcription factors
which respond to and regulate cellular metabolism.
In this study, we demonstrate that naringenin is an agonist of the NRs PPARc and PPARY, and
an antagonist of LXRc. We show that naringenin induces the activation of PPARC and PPARy
ligand-binding domains in GAL4-fusion protein reporters, and induces PPAR response element
(PPRE) activity in Huh7.5.1 human hepatoma cells. Concomitantly, naringenin inhibits the
activation of the LXRa ligand-binding domain in a GAL4-fusion protein reporter in the presence
of the LXRa agonist T0901317. In an in vitro TR-FRET assay, this effect is shown to be at least
partly mediated by the inhibition of the binding of the Trap220/Drip-2 co-activator peptide to a
recombinant LXRc ligand-binding domain. Naringenin also inhibits LXRa response elemenet
(LXRE) activity in Huh7.5.1 cells. Lastly, we show the effects of naringenin on PPARa and LXRax-
driven gene transcription, and that naringenin decreases the secretion of ApoB in Huh7.5.1 cells
and reduces production of triglycerides and bile salts in primary rat hepatocytes.
4.2 Results
Naringenin's manifold effects on cells, including the induction of 1-oxidation, gluconeogenesis
(19), and anti-inflammatory (5) properties, suggest an underlying transcriptional mechanism of
action, similar to the activities of PPARa and PPARy agonists such as fibrates or
thiazolidinediones (TZDs) (20, 21). Therefore, naringenin's effects on the activation of PPARca
and PPARy were investigated using the previously described HeLa-based reporter cell lines,
HG5LN GAL4-PPARa and HG5LN GAL4-PPARy. In these cells, the PPAR ligand binding domain
(LBD) linked to a GAL4 DNA binding domain is expressed constitutively. Upon binding to an
agonist, the PPAR-GAL4 fusion protein activates a luciferase reporter driven by a pentamer of
GAL4 recognition sequences (22).
Naringenin dose-dependently activated PPARca reaching 24%±0.2% induction at 240 iM
(P<0.001) relative to 1 tM of the PPARc agonist GW7647 (Figure 1a). Furthermore, naringenin
activated PPARy up to 57% ± 0.3% at 80 tM (P<0.005) relative to the PPARy agonist 1 tM
BRL49653 (Figure 1b).
To further characterize the interaction between PPARa and naringenin, a LanthaScreen time-
resolved fluorescence resonance energy transfer (TR-FRET) assay was performed. This cell-free
system measures the ability of a compound to enhance the binding of a recombinant PPARa
LBD to a PGC1a co-activator peptide, as measured by an increase in TR-FRET signal. While
GW7647 showed a clear dose-dependent increase (EC5o=2.5nM) in the binding of PGC1a to
PPARa, as expected (Figure 1d), the binding of PGC1a to PPARa did not increase in the
presence of naringenin (Figure 1c), suggesting that naringenin's ability to activate PPARc does
not directly involve enhancement of PPARc binding to PGC1a.
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Figure 1 - Naringenin induces PPARa and PPARy activation through a PGC1a independent mechanism. HGsLN
reporter cells expressing GAL4-PPARax (a) and GAL4-PPARy (b) reporters were treated with increasing
concentrations of naringenin. Naringenin dose-dependently activated PPARca reaching 24%±0.2% induction at 240
[M (P<0.001) relative to 1 M of the PPARa agonist GW7647; and PPARy up to 57% ± 0.3% at 80 [M (P<0.005)
relative to the PPARy agonist 1 M BRL49653. Data is presented as percent activation relative to 1 M GW7647 or
1[tIM BRL49653, respectively. (c) LanthaScreen TR-FRET assay, demonstrating that naringenin did not affect the
binding of the PGC1c co-activator peptide to recombinant PPARa LBD. (d) In contrast, the classical PPARa agonist
GW7647 induces a dose-dependent binding of PGC1a to PPARa in the same assay. (a-b) Conducted by our
collaborator, Dr. Patrick Balaguer of Univ Montpellier I, France.
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4.2.2 Naringenin inhibits LXRa activity via weak partial agonism
Some of naringenin's hypolipidemic effects may be mediated through inhibition of the activity
of the lipogenic LXRc NR. Furthermore, previous research has suggested that naringenin binds
LXRa in vitro (23). To test naringenin's capacity to function as an LXRa antagonist, LXR-alpha-
UAS-bla HEK 293T cells were stimulated with 4.7nM T0901317 (corresponding to the
molecule's EC80 in this system) and then treated with increasing concentrations of naringenin.
Naringenin dose-dependently inhibited LXRa activity, reaching 28.4% ± 0.4% (p<0.01) and
39.1% ± 9.4% (p<0.05) at concentrations of 126pM and 400pM, respectively (Figure 2a).
The interaction between LXRa and naringenin was further characterized using a Lanthascreen
TR-FRET assay. Naringenin enhanced the binding of the LXRa LBD to the Trap 220/Drip-2 co-
activator moderately, yet significantly, in a dose-dependent manner reaching 38.0% ± 2.8%
activation (Figure 2b) compared to the well-studied LXRa agonist, T0901317 (Figure 2c).
Notably, in the presence of 250nM T0901317 (corresponding to the agonist's EC80, as
measured in this system), naringenin dose-dependently inhibited the binding of the Trap
220/Drip-2 co-activator to the LXRa LBD, reaching 15.0% ± 4.1% inhibition (p<0.01) at 133pM
(Figure 2d), consistent with its partial agonism of the receptor.
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Figure 2 - Naringenin inhibits in vitro LXRa reporters through weak agonism. (a) LXR-alpha-UAS-bla HEK 293T cells
were stimulated with 4.7nM T0901317 and exposed to increasing concentrations of naringenin. Naringenin dose-
dependently inhibited LXRct activity, reaching 28.4% ± 0.4% (p<0.01) and 39.1% ± 9.4% (p<0.05) at concentrations
of 126ptM and 400iM, respectively. (b-d) A Lanthascreen LXRa assay was used to assess the ability of naringenin to
enhance binding of the Trap 220/Drip-2 co-activator to the LXRa LBD. Conducted by our collaborator, Dr. Patrick
Balaguer of Univ Montpellier I, France. (b) Naringenin behaved as a weak agonist, enhancing the binding of the
LXRa LBD to the Trap 220/Drip-2 co-activator moderately, yet significantly, in a dose-dependent manner reaching
38.0% ± 2.8% activation. (c) The known LXRa agonist T0901317 strongly enhanced co-activator binding. (d) When
treated with 250nM T0901317, increasing concentrations of naringenin led to an inhibition of the TR-FRET signal,
reaching 15.0% ± 4.1% inhibition (p<0.01) at 133piM.
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4.2.3 Naringenin enhances activity of PPAR and LXRa-driven reporters
To explore the effect of naringenin on PPAR activation more specifically in hepatocytes, we
examined whether the compound would enhance the expression of a PPRE-driven reporter
gene in a hepatoma cell line, Huh7.5.1. First, cells were transfected with a plasmid encoding the
firefly luciferase gene under control of the acyl-CoA oxidase (AOX) PPRE. Renilla luciferase was
used to control for transfection efficiency. Cells were then treated with either increasing
concentrations of naringenin, 10pM WY14,643, a known PPARac agonist, or 10pM ciglitazone, a
PPARy agonist. Naringenin treatment significantly and dose-dependently enhanced luciferase
expression, reaching 17% ± 7% (p<0.05) at 200pM (Figure 3a). Notably, similar levels of
activation were observed when cells were exposed to the known PPAR agonists, WY14,643
(10% ± 5%) and ciglitazone (24% ± 5%).
To test the ability of naringenin to inhibit LXRa-driven gene expression, Huh7.5.1 cells were
transfected with a plasmid carrying the firefly luciferase gene under control of an LXRE. Renilla
luciferase was used to control for transfection efficiency. Naringenin treatment significantly and
dose-dependently decreased the expression of luciferase, reaching a 50.3% ± 2.6% inhibition at
150pM (p<0.001; Figure 3b). Interestingly, at 200pM, LXRE activity was inhibited by 37% ± 5%
(p=0.002). By comparison, one of the few published LXRa-specific antagonist, 5CPPS5 did not
produce a significant decrease in LXRE activity in our hands (Figure 3c) and led to significant
toxicity at higher doses (data not shown).
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Figure 3 - Naringenin activates PPRE-driven and inhibits LXRE-driven gene expression. (a) In Huh7.5.1 cells
transiently transfected with a PPRE-driven luciferase reporter, naringenin dose-dependently enhanced expression
of luciferase reaching 17% ± 7% (p<0.05) at 200pM,similar to the PPAR agonists WY14,643 and ciglitazone. (b) In
Huh7.5.1 cells transiently transfected with an LXRE-driven luciferase reporter, naringenin dose-dependently
suppressed expression of luciferase controlled by LXRE, reaching a 50.3% ± 2.6% (p<0.001) inhibition at 1501M .(c)
5CPPS5 led to no change in LXRE activity. In all experiments, Renilla luciferase was used to account for variability in
transfection efficiencies. 5CPPS5 was a kind gift of Dr. Yuichi Hashimoto, University of Tokyo, Japan.
4.2.4 Naringenin enhances PPARa-regulated genes and decreases lipid secretion
Given our observations regarding naringenin's effects on NRs, we wished to examine its effects
on PPAR- and LXR-regulated gene expression. Prior to measurement of PPARa-regulated mRNA
abundance, cells were grown to confluence and incubated with OptiMEM low-serum media
overnight. Cells were then treated with 200 [tM naringenin for 24 hours and RNA was isolated
for analysis by qRT-PCR (Figure 4a,b). Naringenin induced PPARa-regulated genes CYP4A11/22,
ACOX, and ApoAl by 68%, 31%, and 25%, respectively. Naringenin also reduced the expression
of LXRa-regulated genes ABCA1, LXRa, and ABCG1 by 92%, 60%, and 27%, respectively.
Interestingly, naringenin also modulated the expresssion of other transcription factors, such as
SREBP1 and PPARy (Figure 4c).
We have previously shown that naringenin treatment reduces the secretion of VLDL (24). As our
results suggest that naringenin exerts its effects partly through activation of PPARs, we next
examined the effects of the PPARa and PPARy agonists, WY14,643 and ciglitazone, on the
secretion of ApoB. Huh7.5.1 cells were stimulated for 24 hours with 200[M naringenin, 10p M
WY14,643, or 10 tM ciglitazone, and media was collected and analyzed (Figure 4d). Predictably,
naringenin treatment led to a 73% ± 9% (p<0.001) reduction in ApoB production. This compared
with a 33% ± 12% (p<0.01) reduction produced by treatment with WY14,643. Treatment with
cigilitazone did not lead to a significant change in VLDL production.
Lastly, we wished to examine naringenin's effects on several key metabolites. Specifically, we
predicted that naringenin treatment would reduce the secretion of triglycerides from cells and
that bile acid production would be reduced due to suppression of the LXRc pathway (25, 26).
Primary rat hepatocytes were stimulated with 200 tM and media was analyzed for urea,
triglycerides, and bile salts content (Figure 4e). Naringenin treatment led to a 61% ± 19%
(p<0.001) reduction in triglyceride accumulation in the medium and a 32% ± 11% (p=0.005)
reduction in bile salt production. Urea accumulation in the media did not change significantly,
however.
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Figure 4 - Naringenin regulates PPARa- and LXRa-controlled genes and inhibts lipid secretion. Cells were treated
with 200 [tM naringenin for 24 hours as described and RNA was isolated for analysis by qRT-PCR. (a) Naringenin
induced PPARa-regulated genes. CYP4A11/22, ACOX, and ApoAl were induced 68%, 31%, and 25%, respectively.
(b) Naringenin reduced the expression of LXRc-induced genes. ABCA1, LXRa, and ABCG1 were downregulated by
92%, 60%, and 27%, respectively. (c) Huh7.5.1 cells were stimulated for 24 hours with 200tM naringenin, 10siM
WY14,643, or 10sAM ciglitazone, and media was collected and analyzed. Naringenin treatment led to a 73% ± 9%
(p<0.001) reduction in ApoB production, while WY14,643 led to a 33% ± 12% (p<0.01) reduction. Treatment with
cigilitazone did not lead to a significant change in VLDL production. (d) Primary rat hepatocytes were stimulated
with 200[iM and media was analyzed for urea, triglycerides, and bile salts. Naringenin treatment led to a 61% ±
19% (p<0.001) reduction in triglyceride accumulation and a 32% t 11% (p=0.005) reduction in bile salt production.
Urea accumulation in the media did not change significantly.
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4.3 Discussion
Dysregulation of lipid and carbohydrate homeostasis is associated with multiple disease states,
including metabolic, inflammatory, and infectious disorders (27). Metabolic regulation is
achieved in mammals through an intricate mechanism that responds to multiple physiological
cues. The response to dietary glucose, for example, is highly dependent on secretion of insulin
and inhibition of glucagon secretion by pancreatic alpha and beta cells (28). In hepatocytes,
both insulin and glucose metabolites induce expression of genes encoding glucose transporters
and glycolytic and lipogenic enzymes, such as the L-type pyruvate kinase (L-PK), acetyl-CoA
carboxylase (ACC), and fatty acid synthase (FASN) (29). Concomitantly, genes of the
gluconeogenic pathway, such as the phosphoenolpyruvate carboxykinase gene, are
downregulated (28, 30).
In recent years, several NRs have emerged as key regulators of cellular metabolism (26, 31, 32),
with specific metabolites shown to be their natural ligands: LXRs respond to oxysterols and
glucose (33, 34), the farnesoid X receptor (FXR) which responds to bile acids (35), and PPARs,
which respond to fatty acids (36).
The PPAR family of NRs includes PPARc, PPARy, and PPAR6. The prevalence of these receptor
subtypes varies in different tissues, with PPARa being the most prevalent subtype in the liver,
and PPARy the most abundant in adipose tissue (20). PPARa is activated by fatty acids released
in a physiologicalfasting state, leading to increased 1-oxidation and gluconeogenesis (37, 38).
In clinical practice, PPARa agonists (fibrates) are used to treat hyperlipidemia, whereas PPARy
agonists (TZDs) are used to increase insulin sensitivity (21, 39).
The LXR family of NRs includes both LXRa and LXR3 (33, 34, 40). The latter is ubiquitously
expressed, while the former is found primarily in the liver, adipose tissue, and macrophages
and is activated by the abundance of glucose and sterols (41), typical of a physiologicalfed
state. In the liver, following activation by its ligands, LXRa activates lipogenic and glycolytic
genes partly through activation of SREBP-1c (42, 43). Several of these genes are involved in the
production of VLDL and its secretion by hepatocytes (44).
Following the binding of a ligand, both PPARs and LXRs become activated and heterodimerize
with another NR, the retinoid X receptor (RXR) (31). The activated heterodimer then binds
conserved response elements in specific genes, while recruiting other co-regulatory molecules,
such as the co-activators PGC1a (45) and Trap220 (46) for PPARa and LXRa, respecitvely. The
requirement of both LXR and PPAR for the RXR binding partner leads to competitive inhibition
at the level of receptor activation, offering a transcriptional layer of control over fasted-to-fed
transition (18, 47, 48). The existence of both a PPRE and an LXRE in the regulatory region of the
LXRa gene (49, 50) suggests further levels of cross-regulation. Lastly, other coactivators,
corepressors and kinases, such as P13K and ERK, can regulate nuclear receptor activity by non-
transcriptional mechanisms (51-53).
Naringin is an abundant citrus flavonoid responsible for the bitter taste in grapefruit. Naringin is
hydrolyzed to its aglycone form, naringenin, prior to being absorbed in the intestine. Naringenin
has been reported to be an antioxidant with demonstrated hypolipidemic, anti-carcinogenic
and anti-inflammatory properties (5). The molecular mechanism behind naringenin's
hypolipidemic effect has been studied mainly in HepG2 cells, where naringenin was shown to
reduce the secretion of VLDL and LDL (54, 55) through the inhibition of ACAT2 and MTP (54,
56), critical enzymes for VLDL assembly. Allister et al. demonstrated that this inhibition is
regulated primarily through the mitogen-activated protein kinase pathway, through MEK1/2
and ERK1/2 (56). In addition, naringenin was shown to upregulate LDL receptor (LDL-R) (23),
whose expression in the ER leads to the degradation of ApoB (57, 58). This induction of LDL-R
transcription was shown to be caused by activation of P13K upstream of SREBP-1 (23).
Naringenin has also been shown to inhibit HMGR (59), while activating enzymes important in
fatty acid oxidation such as CYP4A1 (60). These myriad effects suggest that the flavonoid's
target might be at the nuclear receptor level. Strengthening this hypothesis is the anecdotal
report that naringenin interacts with LXR (23) and, more recently, that it activates PPARa in U-
20S cells (61). A similar pathway was demonstrated for green tea polyphenols, soy isoflavones,
and the citrus flavone tangeretin, which regulate LXRa and PPARa (62, 63).
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In vivo studies provide further evidence of naringenin's hypolipidemic effects. In a recent
clinical trial, a daily 400 mg dose of naringenin was shown to reduce circulating LDL levels by
17% in hypercholesterolemic patients (7). Similar cholesterol lowering effects of naringenin
have been demonstrated in rabbits (8, 9) and rats (10).
In our study, we first showed that naringenin functioned as a PPARa and PPARy agoinst in a
reporter cell line. In this system, a previously described HeLa cell line was used, in which either
the PPARa or PPARy LBD attached to a GAL4 DNA binding domain was being constitutively
expressed (22). Luciferase expression was driven by a GAL4 upstream activating sequence
(UASG) in response to the activity of agonists on the NR LBD. Our results demonstrate that
naringenin significantly activated both PPARa and PPARy compared to known agonists.
Next, a LanthScreen time-resolved fluorescence resonance energy transfer (TR-FRET) assay was
used to explore further the direct effect of naringenin on the PPARa LBD. In this cell-free assay,
a donor fluorophore is attached to PGC1c, a PPARa co-activator, while an acceptor flurophore
is attached to the LBD of PPARa. A conformational shift induced by agonist binding increases
the affinity of the co-activator for the LBD, and leads to enhanced binding and an increase in
FRET. In this assay, while increasing concentrations of GW7647, a known PPARa agonist, led to
an increase in FRET signal, no such increase was observed in response to naringenin up to a
concentration of 133pM, suggesting that PPARa activation does not occur through a direct
enhancement of PPARc's affinity for the PGC1a co-activator.
To examine the ability of naringenin to drive PPRE-regulated gene expression, we transiently
transfected Huh7.5.1 cells, a heptoma-derived cell line, with a previously described PPRE-driven
reporter plasmid (17). This plasmid encodes two copies of the AOX PPRE upstream of the firefly
luciferase reporter, and has been demonstrated to respond to PPAR agonists. We showed that
naringenin significantly increased the expression of the PPRE-driven luciferase. Furthermore,
PPRE activation was statistically similar to that obtained using both WY14,643 and ciglitazone.
In our hands, PPRE activation by naringenin was critically dependent on culture conditions:
when cells were seeded at low density or were not serum-starved prior to stimulation,
naringenin's effect on PPRE activation was either abolished or reversed (data not shown),
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suggesting that naringenin's effect on PPAR induction is dependent on the metabolic state of
the cell. This phenomenon is currently under further investigation.
We next tested the ability of naringenin to inhibit LXRa, as the inhibition of LXRa activity would
be expected to lead to a decrease in VLDL secretion. First, as in the case of PPAR, the effect of
naringenin on activation of an LXRa-GAL4 chimera was examined in a reporter cell line.
GeneBlazer LXR-alpha-UAS-bla HEK 293T cells were treated with T0901317 at the agonist's
EC80 (250nM) and increasing concentrations of naringenin, and the resulting signal was
quantified. Naringenin inhibited LXRa activity in this system significantly. Given these results,
we continued to explore the mechanism of LXRa inhibtion using a LanthaScreen LXRa TR-FRET
assay. Analogously to the PPARa LanthaScreen assay, this assay measures the FRET between a
donor flurophore bound to the Trap-220 co-activator and the LXRa LBD. At concentrations
higher than 100[iM, naringenin increased the FRET signal moderately, but significantly,
consistent with the behavior of a weak agonist of LXRa. This suggested that when co-applied
with T0901317, naringenin would act as an antagonist. Indeed, we observed a reduction in the
FRET signal when increasing concentrations of naringenin were added in the presence of
T0901317. These results suggest the naringenin's inhibitory effect on LXRa could in part be the
result of competitive inhibition with the NR's natural ligands.
To examine the ability of naringenin to inhibit the activity of an LXRE-driven gene expression,
Huh7.5.1 cells were transiently transfected with an LXRE-driven reporter plasmid (18) and
treated with increasing concentrations of naringenin in the presence of T0901317. Naringenin
dose-dependently inhibited luciferase expression, reaching 50.3% at 150PM. Interestingly,
mirroring the decreased activation of PPARy observed in the PPARy-GAL4 system at higher
concentrations, LXRE activity was also higher at 200pM than at 150pM.
We next wished to examine the effects of naringenin on gene transcription and metabolism.
Huh7.5.1 cells were treated with naringenin and analyzed for changes in mRNA abundance by
qRT-PCR. Genes involved in p-oxidation and reverse cholesterol transport, CYP4A11/22, ACOX,
and ApoAl increased by 68%, 31%, and 25%, respectively. Naringenin also reduced the
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expression of LXRc-regulated genes involved in glucose transport and lipogenesis, ABCA1,
LXRa, and ABCG1 by 92%, 60%, and 27%, respectively.
Naringenin's effects on NRs and their downstream genes led us to hypothesize that cells
treated with the flavonoid would produce less triglycerides and bile salts, specifically in rat
hepatocytes, as LXRc activation has been shown to drive lipid and bile synthesis in rats (25, 26).
Primary rat hepatocytes treated with naringenin indeed secreted less triglycerides and bile salts
than untreated controls. Importantly, urea secretion was maintained, suggesting naringenin'
effects were not simply a result of cell death or loss of function.
Lastly, we examined the effects of other PPAR agonists on ApoB production. Huh7.5.1 cells
were treated with naringenin, WY16,463 (PPARt agonist) or ciglitazone (PPARy agonist).
Naringenin and WY16,463 treatment led to significant reductions in ApoB secretion. Notably,
naringenin's effect was significantly more pronounced than that of the PPARa agonist's.
Furthermore, the PPARy agonist, ciglitazone, did not change the production of ApoB
significantly. These results suggest that in Huh7.5.1 cells, naringenin's PPARc activation is more
important than its PPARy activation in blocking VLDL production; and that other mechanisms,
such as LXRa inhibition are likely contributing to the observed reduction, as well.
Several other investigations have analyzed the effects of small molecules on PPAR- and LXRa-
driven gene activation. While many of these have demonstrated significant changes in response
to suggested ligands, most have involved the over-expression of one or more nuclear receptors.
While this has the obvious advantage of increasing signal-to-noise ratios, over-expression of
receptors could result in a distortion of the cellular network of interacting NRs. We therefore
chose not to over-express NRs, and rather to study the effects of naringenin in a heptoma cell
line that contains limited amounts of these nuclear receptors.
Other mechanisms of naringenin's effect on lipid production and mobilization have been
proposed. Huff and colleagues have extensively characterized the effects of naringenin on both
insulin and MAPK signaling pathways. Specifically, naringenin was shown to inhibit the activity
of MTP, the rate-limiting enzyme in VLDL assembly, through the activation of MAPK signaling,
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leading to a decrease in VLDL secretion in HepG2 cells (56). Furthermore, naringenin activates
P13K signaling, leading to the upregulation of LDL-R expression (23), which has been shown in a
separate study to lead to a degradation of ApoB in the ER (57, 58). While our observations are
generally consistent with these previous studies, some minor discrepancies could be explained
by differences in experimental conditions, such as cell types that were used and time scales
that were examined. The relationship between naringenin's previously described mechanisms
of action and its effects on nuclear receptor signaling - whether causative, associative, or
independent - remains to be established.
Naringenin's ability to decrease VLDL secretion by hepatocytes could lead to benefits in treating
varied disease states, including atherogenic processes and infectious disease. The
antiatherogenic effects of naringenin have been widely explored, most recently in mice (19).
The ability of the molecule to agonize both the PPARa and PPARy receptors, suggest it could
have both anti-lipogenic effects and insulin-sensitzing properties, as has been clinically
demonstrated by the fibrate (PPARa agonist) and TZD (PPARy agonist) classes of drugs,
respectively. Indeed, dual PPARc and PPARy agonists have recently been investigated as
normoglycemic and antiatherogenic agents (64).
Recently, our group has shown that naringenin inhibits the secretion of ApoB from HCV-
infected Huh7.5.1 cells, and that inhibition of VLDL secretion from hepatocytes leads to a
decrease in HCV particle accumulation in media (24). Other groups have demonstrated similar
reductions in virus secretion in response to inhibition of VLDL production and secretion (65, 66).
We are currently conducting a clinical trial to explore the possible effects of short-term
naringenin treatment in non-responsive HCV patients. Recently, it has been demonstrated that
lipogenic changes observed in hepatitis B (HBV)-associated hepatic steatosis are mediated by
the induction of LXR and its target genes by the viral HBx protein (67, 68). Due to naringenin's
inhibitory effects on LXR, the molecule could prove useful in abating the steatotic process
associated with HBV infection.
Lastly, there is increasing evidence for the link between metabolic, inflammatory, and
infectious disease (69). Atherosclerosis is known to be mediated by inflammatory processes,
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and recent evidence suggests that drugs designed to mitigate atherogenesis, such as statins,
exert part of their clinical benefits through their anti-inflammatory effects (70). Similarly, a large
body of work has demonstrated the detrimental effects of inflammation on the liver in the
context of viral hepatitis, steatosis, and the development of hepatocellular carcinoma (71).
Naringenin's anti-oxidant, anti-inflammatory, anti-thrombotic, and vasodilatory effects, could
increase the potential of the molecule's therapeutic potential.
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4.4 Materials and Methods
Reagents
Fetal bovine serum (FBS), phosphate-buffered saline (PBS), Dulbecco's modified Eagle medium
(DMEM), penicillin, streptomycin, trypsin-ethylene diamine tetraacetic acid (EDTA), OptiMEM
basal medium, and Lipofectamine 2000 were obtained from Invitrogen Life Technologies
(Carlsbad, CA). Insulin was obtained from Eli-Lilly (Indianapolis, IN). Dual luciferase assay kit was
purchased from Promega (Madison, WI). Unless otherwise noted, all other chemicals were
purchased from Sigma-Aldrich Chemicals (St. Louis, MO).
Cell culture
The Huh7.5.1 human hepatoma cell line was kindly provided by Dr. Chisari (Scripps Research
Institute, La Jolla, CA) and Dr. Wakita (National Institute of Infectious Diseases, Tokyo, Japan),
respectively. Huh7.5.1 cells were cultured in DMEM supplemented with 10% FBS, 200 units/mL
penicillin, and 200 mg/mL streptomycin in a 5% CO2-humidified incubator at 37"C. Huh7.5.1
cells were passaged every 3 days and used at passage <15.
GAL4-nuclear receptor activation assays
PPAR activation was examined as previously described using the HGLN5 cell line. Briefly, HeLa
cells were stably transfected with the p(GAL4RE)5-3Glob-Luc-SVNeo plasmid, encoding the
firefly luciferase gene driven by a pentamer of yeast activator GAL4 binding sites in front of $-
globin promoter. Cells were subsequently stably transfected with either pGAL4-PPARa-puro, or
pGAL4-PPARy-puro, encoding amino acids 1-147 of GAL4, followed by a short linker and the
ligand binding domain of either PPARa or PPARy, resecitvely. HGLN5 cells were treated with
varying amounts of ethanol-dissolved naringenin and luciferase activity was compared to that
of known agonists of PPARa and PPARy, GW7647 or BRL49653, respectively.
LXRa activation was investigated using the GeneBLAzer Beta-lactamase reporter technology
(Invitrogen SelectScreen Cell-Based Nuclear Receptor Profiling Service, Madison, WI). LXR-
alpha-UAS-bla HEK 293T cells were thawed and resuspended in Assay Media (DMEM phenol red
free, 2% CD-treated FBS, 0.1 mM NEAA, 1 mM Sodium Pyruvate, 100 U/mL/100 pg/mL
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Pen/Strep) to a concentration of 312,500 cells/mL. The control agonist T0901317 at the pre-
determined EC80 concentration (4.7 nM) was added to wells containing variable concentrations
of naringenin. The plate was incubated for 16-24 hours at 37*C/5% CO2 in a humidified
incubator. Substrate Loading Solution was added to each well and the plate is incubated for 2
hours at room temperature. The plate is read on a fluorescence plate reader. Results for each
concentration (n=4) are reported as percent activation of T0901317-stimulated, naringenin-
free controls.
TR-FRET Assays
LanthaScreen TR-FRET Coactivator Assays were used to identify agonists and/or antagonists of
PPARa and of LXRa. In these cell-free assays, ligands are identified by their ability to bind the
LBD of the respective receptor and induce a conformational change that results in recruitment
of a fluorescein-labeled coactivator peptide. A purified, glutathione S-transferase (GST)-tagged
PPAR alpha or LXRa ligand-binding domain (LBD) is indirectly labeled using a terbium-labeled
anti-GST tag antibody. Recruitment of fluorescein-labeled coactivator peptide - PGC1a for
PPARa or Trap220 for LXRct - is measured by monitoring fluorescence resonance energy
transfer (FRET) from the terbium-labeled antibody to the fluorescein on the peptide, resulting
in a high TR-FRET ratio (520 nm:490 nm emission). Test compounds were diluted in 100%
DMSO, and assays were run per the manufacturer's instructions. Briefly, to test the ability of a
molecule to function as an NR agonist, increasing concentrations of either naringenin or a
control agonist were added to wells containing NR LBD and co-activator peptide solutions. To
test the ability of a molecule to function as an LXRa antgonist, a similar protocol was followed,
but 250nM T0901317 (EC80 of the agonist, as measured in this assay) was added to all wells. In
both agonist and antagonist modes, following 1 to 2 hour incubation at room temperature, the
520/490 TR-FRET ratio was measured with a PerkinElmer Envision fluorescent plate reader with
TRF laser excitation using the following filter set: excitation 330 nm, emission 495 nm, and
emission 520 nm. A 100 ps delay followed by a 200 ps integration time was used to collect the
time-resolved signal. Results are displayed as percent activation compared to maximal
activation of positive control.
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PPAR and LXRa response element luciferase reporter assays
To examine the ability of naringenin to drive luciferase expression from a PPRE- or LXRE
response element reporter, Huh7.5.1 cells were transiently transfected with one of two
previously described reporter plasmids, pAOx(x2)luc or pDR4(X2)luc, respectively (17, 18). The
pRL-TK plasmid (Promega, Madison, WI), which constitutively expresses renilla luciferase under
the control of the thymidine kinase promoter, was co-transfected to control for transfection
efficiency. To examine PPRE-driven expression, pAOx(x2)Iuc was transfected into Huh7.5.1
cells, which were kept in OptiMEM for 22hrs following transfection. Media was then replaced
by DMEM supplemented with 10% FBS, 200 units/mL penicillin, and 200 mg/mL streptomycin
along with variable concentrations of naringenin, the known PPARa agonist WY14,643, or the
known PPARy agonist, ciglitizone. After 24 hours, cells were lysed in Passive Lysis Buffer
(Promega). The ratio of firefly luciferase to renilla luciferase luminescence was quantified using
a Dual Luciferase Assay kit (Promega) following the manufacturer's instructions on a FB12
Single Tube Luminometer (Berthold Technologies USA, Oak Ridge, TN). To examine LXRE-driven
expression, cells were similarly transfected and treated with 1M T0901317 along with varying
concentrations of naringenin. Lysis and signal quantification were carried out as above.
Naringenin was dissolved in DMSO. DMSO levels were equal in all samples and never exceeded
0.5%. Results are reported as percent activation compared to untreated (DMSO-only) controls.
qRT-PCR
Following a 4-hour stimulation, cells were lysed with RLT Plus buffer containing -
mercaptoethanol and RNA was isolated using RNeasy Mini Kit on a QIACube device (Qiagen,
Valencia, CA). Total RNA was quantified on a ND-1000 spectrophotometer (NanoDrop
Technologies, Rockland, Del.) and mRNA transcript abundance was measured on a MyiQ Real-
Time PCR Detection System using iScript One-Step RT-PCR Kit With SYBR Green (Bio-Rad,
Hercules, CA), according to the manufacturers' instructions. Primers used in these reactions
(Integrated DNA Technologies, Coralville, IA) were designed using the PRIMER-BLAST program
and appear in Table 1. The Insulin Signaling Pathway PCR Array from SABiosciences was used
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with a RT2 First Strand Kit for
a Strategene Mx3000 cycler.
Table 1 - List of primers used
reverse transciption and RT2 qPCR Master Mix (Frederick, MD) on
for qRT-PCR analysis.
ApoB secretion analysis
Huh7.5.1 cells were incubated overnight in OptiMEM I media. Cells were then treated with
media containing naringenin for 24 hours, and then media was collected and analyzed. ApoB
was quantified in the medium using the ALerCHEK, Inc. (Portland, ME), total human ApoB ELISA
kit. Media was diluted 1:10 with the specimen diluent, and the assay was carried out according
to the manufacturer's directions.
Metabolite assays
To assess the amount of triglycerides that were produced by the cultured hepatocytes,
Triglyceride Reagent and the Free Glycerol Reagent were used. The two reagents were
combined into a working stock solution by creating a 4 to 1 mixture of Triglyceride Reagent and
Free Glycerol Reagent, respectively. Briefly, in the assay, triglycerides are broken down into
glycerol backbones and hydrocarbon chains. The glycerol backbone then reacts with the Free
Glycerol Reagent and is read at 540 nm on a spectrophotometer. 2 d of media were added in a
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Gene Primers
CYP4A11/22 ACT GGC TCT TCG GGC ACA TC
ACA CGA ACT TTG CCT CCC CA
ACOX TGG CAC ATA CGT GAA ACC GC
CGCTGTATCGGATGG CAATG
ApoAl AAA GCT GCG GTG CTG ACC TT
CGC TGT CTT TGA GCA CAT CCA
LXRa GCT CCT TTT CTG ACC GGC TT
TGA ATT CCA CTT GCA GCC CT
ABCA1 TCT GGA AAG CTC TGA AGC CG
TGA GTT CCT CCC ACA TGC CT
ABCG1 ACC GGG GAA AAG TCT GCA AT
TCA CCA GCC GAC TGT TCT GA
96 well plate to 200 [d of working stock solution and allowed to incubate at 372C for 5 minutes.
After incubation, the amount of glycerol in the solution was assayed on a spectrophotometer
plate reader at 540 nm.
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5 Enhancement of Naringenin Bioavailability by Complexation
with Hydroxypropoyi-p-cyclodextrin
5.1 Introduction
The ability of naringenin to significantly reduce plasma cholesterol levels has been
demonstrated both in vivo and in vitro (1-3). Naringenin's clinical relevance is limited, however,
by low solubility and bioavailability owing in part to its largely hydrophobic ring structure. In
this study, p-cyclodextrins were examined as potential excipients to enhance the solubility and
enteral uptake of the flavonoid. Cyclodextrins are a family of cyclic oligosaccharides that create
a 3-dimensional toroid structure, providing a cavity that can accommodate small hydrophobic
molecules. Cyclodextrins can therefore be used as excipients to improve the solubility of
hydrophobic drugs and other molecules (4, 5). Specifically, the bioavailability of rutin, a
flavonoid-glycoside similar in structure to naringin, was significantly enhanced by complexation
with 2-hydroxypropyl-p-cyclodextrin (HPICD) (6).
Here, we demonstrate that 2-hydroxypropyl--cyclodextrin (HPpCD), enhances the
solubility of naringenin, its transport across a Caco-2 model of human gut epithelium, and its
plasma concentrations following oral administration to Sprague-Dawley rats. Combined with
HPICD's strong safety record, our results suggest that naringenin-HPPCD complexes could be
used to achieve clinically relevant doses of the flavonoid in patients for the treatment of
dyslipidemia and HCV infection.
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5.2 Results
5.2.1 O-Cyclodextrins increase the solubility of naringenin
Molecules similar to naringenin in structure and size were previously shown to be solubilized by
complexation with P-cyclodextrin (7). To explore if naringenin is similarly solublized we
generated complexes with P-cyclodextrin (pCD), methyl P-cyclodextrin (mICD), and 2-
hydroxypropyl-p-cyclodextrin (HPfCD). UV analysis indicated that complexation with
cyclodextrins resulted in a very small shift in naringenin's absorption spectrum (Figure 1B).
Concentrations of naringenin were then extrapolated from the previously obtained standard
curve (Figure IC). As expected, naringenin solubility in water was 36 tM - 1 M, consistent with
previously observed results (8). Upon complexation with cyclodextrins, the amount of
solubilized naringenin increased considerably, as summarized in Table 1. The three pCDs
solubilized naringenin in decreasing order mICD > HP3CD > 3CD resulting in a significant 526,
437, and 132-fold, enhancement in solubility respectively (p < 0.001).
Max. Naringenin Corresponding Fold increase in Keq
Conc. (mM) CD Conc. (mM) solubility
PCD 4.8 t 0.3 20 1 132 6025
mPCD 19 0.9 50 ± 2.5 526 9975
HPPCD 15.8 t 1.4 50 -12.5 437 8203
Table 1 - Naringenin solubility in cyclodextrin solutions.
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Figure 1 - Cyclodextrins enhance the solubility of naringenin in aqueous solution. (a) A standard curve of
naringenin concentration vs. its absorption peak at a wavelength of 290nm (b) Cyclodextrin solutions saturated
with naringenin were analyzed by UV absorbance. Complexation with cyclodextrins resulted in a very small shift in
naringenin's absorption spectrum. (c) Naringenin concentrations were extrapolated from the previously obtained
standard curve. Naringenin solubility in water was 36[tM ± 1p.M, whereas the amount of solubilized naringenin
increased considerably with addition of pCD, mICD, or HPPCD (132-, 526-, 437-fold, respectively). (a,c) Conducted
by Carolyn Lee-Parsons of Northeastern University.
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5.2.2 HP$CD enhances the transport of naringenin across a Caco-2 monolayer
While m$CD was most effective in enhancing the solubility of naringenin, its use is
associated with soft tissue and kidney damage due to its detergent-like effect on membranes
(9). On the other hand, HP3CD does not cause hemolysis or irritation due to its low surface
tension, and is has been approved as an excipient by the FDA (10). We therefore examined the
ability of HP$CD to enhance the transport of naringenin across a monolayer of Caco-2 cells, an
established model for drug transport across the human gut epithelium.
Caco-2 cells were grown for 21 days on collagen-coated 24 mm diameter porous
transwell membranes (3 pm pores) on which cells form differentiated monolayers, expressing
major tight junction proteins, microvilli, and drug transporters (Figure 2A) (80, 81). Epithelial
integrity and maturity of the monolayers was evaluated by measuring the transport of Lucifer
yellow across the monolayer. 11mM naringenin, either alone or in a complex form with 45mM
HP$CD, was added to the top assay chamber. Samples were taken from both the top, apical
chamber and the bottom, basal chamber at different time intervals and assayed for
concentrations of naringenin (Figure 2B). The integrity of the Caco-2 monolayer was verified at
the end of the experiment by measuring the transport of Lucifer yellow. In the presence of
HP3CD, the concentration of naringenin at the basal chamber was increased from 0.04 tM
0.02[tM to 0.51 tM t 0.07 M, representing an 11-fold enhancement of transport across the
Caco-2 monolayer. The integrity of the monolayer prior to and following the experiment was
similar to controls for both treatments.
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Figure 2 - HP$CD enhances transport of naringenin across Caco-2 cell monolayer. (a) Caco-2 cells were grown for
21 days on collagen-coated 24 mm diameter porous transwell membranes, forming a monolayer. (b) 11mM
naringenin, either alone or in a complex form with 45mM HPICD, was added to the top assay chamber. In the
presence of HPICD, the concentration of naringenin was increased in the basal side from 0.04pLM ± 0.02[tM to
0.51sM ± 0.07ptM, representing an 11-fold enhancement of transport across the Caco-2 monolayer. Conducted by
Ofra Benny of Harvard Medical School, Boston.
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5.2.3 HPPCD enhances the bioavailability of naringenin in rats
To test whether cyclodextrin would enhance the oral bioavailability of naringenin, adult
Sprague-Dawley rats were fed 20mg/kg body weight naringenin either alone, or as a 1:16
(wt/wt) HPPCD-naringenin complex, using an oral gavage. Blood samples were collected
sequentially at 0, 15, 30, 60, 120, 240, 360, 510, and 600 min from the carotid artery using the
previously placed catheter into tubes containing heparin. Immediately after collection, plasma
was separated and stored at -80'C for further analysis. At the conclusion of the experiment, all
animals were sacrificed, and liver, kidney, and bowel specimens were collected for histology. In
an additional experiment, animals were placed in metabolic cages and urine was collected and
pooled for the duration of the experiment. Total naringenin (flavonoid and glycoside) was
determined by LC-MS as described above.
The complexation of HPjCD with naringenin significantly affected the plasma
concentration versus time profile of the flavonoid (Figure 3a). Complexation with HPICD
significantly increased the AUCo_10 of naringenin from 2.0 - 0.5 hr* tg/mL to 15.0 4.9
hr* tg/mL representing a 7.4-fold increase in bioavailability (p=0.005 n=3). Naringenin's
maximal concentration, Cmax, increased from 0.3 t 0.1 [tg/mL to 4.3 ± 1.2 tg/mL representing a
14.6-fold increase (p=0.002 n=3). The calculated half-life for naringenin in plasma was 2.28
hours, consistent with values previously reported in humans (11) and rats (28). Finally, analysis
of urine samples in two animals demonstrated renal clearance of 4.2 ! 1%.
Naringenin concentrations in plasma were fitted to a two-compartment
pharmacokinetic model (Figure 3b). This model suggests that naringenin is transported from
the lumen into plasma over 4000-fold the rate than when it is not complexed with cyclodextrin
(k1,complexed = 74.6834s vs. k1,uncomplexed= 0.0177 s1). The k2 clearance parameter was assumed
to be constant, and calculated to equal 0.3138 s- .
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5.2.4 Oral administration of HPSCD-naringenin was not associated with adverse effects
Lastly, we wished to examine if the administration of the HPSCD-naringenin complex
was associated with tissue or organ damage. Liver, kidneys and intestine were removed 10 hrs
following oral administration of the complex and showed no gross pathological changes (data
not shown). Histological characterization by a blind observer demonstrated that the small
intestine, kidney, and liver sections showed no evidence of tissue injury or inflammation in both
groups. Liver sections showed no evidence of hepatocyte damage or neutrophil infiltration to
the portal area, while kidney and intestine sections show no tubular/glomerular damage,
edema or epithelial damage, respectively (Figure 4). One intestine section in a single rat
showed a localized small infiltrate, which did not appear to be related to the experiment.
Serum samples were taken from the rats 10 hours after the treatment with HP0CD-
naringenin complex, naringenin alone as well as rats treated with saline as a control. The
biochemical examination of BUN, ALT/AST, total protein and glucose as parameters of renal and
liver function showed no statistical difference between these three groups (Table 2). Together
with the histological and pathological analysis these results suggest that oral administration of
HPBCD-naringenin complex was not associated with any adverse effects.
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Figure 3 - HPPCD enhances oral bioavailability of naringenin in rats. (a) Male Sprague-Dawley rats were fed
20mg/kg body weight naringenin either alone, or as a HPI3CD-naringenin complex. Blood samples were collected
sequentially at 0, 15, 30, 60, 120, 240, 360, 510, and 600 min, and subsequently analyzed for naringenin content by
LC-MS. Complexation with HPI3CD enhanced oral bioavilability as measured by AUCO-10 of naringenin from 2.0 -t 0.5
hr*[tg/mL to 15.0 ±- 4.9 hr*tLg/mL representing a 7.4-fold increase in bioavailability (p=0.005, n=3); and maximal
concentration, Cmax increased from 4.3 ±L 1.2 [tg/mL to 0.3 ±t 0.1 [tg/mL representing a 14.6-fold increase (p=0.00 2,
n=3). (b) Plasma concentrations were fitted to a two-compartment pharmacokinetic model. Naringenin is
transported from the lumen into plasma over 4000-fold the rate than when it is not complexed with cyclodlextrin
(kl,complexed = 74.6834s-1 vs. kl,uncomplexed = 0.0177 s-i). The k2 clearance parameter was assumed to be constant, and
calculated to equal 0.3138 s-1.
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Kidney
Figure 4 - Rats were fed either naringenin (bottom) or naringenin complexed with HPICD (top) in PBS. Blood
samples were drawn at various time points, and at t=10hrs animals were sacrificed and tissue specimen from each
animal was immediately collected and preserved. Representative images of H&E histological preparations from
bowel (left), kidney (center), and liver (right) are presented. The tissues appear normal with no signs of
inflammation or necrosis.
Na+ + :1- ilu a 3un 're ALP ALT AST ~Bil Alb P
NNCD Avg 39.0 .9 02.0 168.0 .3 .6.7 .2 147.3 i6.7 307.3 .3 .6 .6
SD .0 .6 .0 14.4 .7 3.1 ).0 4.6 11.1 .07.8 ).0 .2 .5
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Table 2- Metabolic blood panel of experimental animals compared with untreated controls. Glu, Glucose; BUN,
blood urea nitrogen; Cre, Creatinine; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate
transaminase; TP, total protein. Statistically significant values (p<0.05) are noted in italics.
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5.3 Discussion
Naringenin has been the focus of multiple studies in recent years, which have began to
elucidate its clinical potential with anti-atherogenic, antioxidant, anti-inflammatory, and
hypolipidemic effects (12). These properties make it an interesting candidate for clinical
application. As with other drugs, however, efficacy would depend on the ability to reproducibly
deliver the molecule to patients (7). The ability to breakdown naringin to the absorbable
naringenin form varies widely between patients, possibly owing to differences in gut flora (13).
Thus, a method of enhancing the bioavailability of naringenin itself is required.
Cyclodextrins, a family of cyclical oligosacchrides composed of varying numbers of
glucopyranoside rings that form a three-dimensional toroid structure, are widely used in the
food and pharmaceutical industries to solubilize hydrophobic drugs. The potential of I-
cyclodextrins to enhance the solubility and gut absorption of flavonoids was demonstrated by
the complexatoin of the flavonoid-glycoside, rutin, with HPPCD, and found an >10-fold increase
in its solubility in aqueous solution and a 3-fold increase in plasma concetration, as measured
by area-under-the-curve (AUC) (14)
We began by examining the ability of several s-cyclodextrins to enhance to solubility of
naringenin. Naringenin is generally known to suffer from low solubility in aqueous
environments, and is generally dissolved in organic solvents (6). Our observations confirmed a
low level of solubility in aqueous buffer, reaching 36 M. The addition of increasing amounts of
@-cyclodextrins, however, led to enhanced ability to solubilize the flavonoid. Remarkably, the
3CDs increased naringenin's solubility by 2-3 orders of magnitude, up to >500-fold. Of the three
pCDs, solubility increased in the order mpCD>HP3CD>CD. Despite the superior ability of mICD
to solubilize naringenin, we chose to conduct further experiments with HP3CD, which does not
or exert a detergent-like effect on biological membranes causing irritation and hemolysis (15).
HP$CD is generally regarded as safe by the FDA for use as an excipient (9).
We next examined the ability of HPPCD to enhance the delivery of naringenin across the
intestinal mucosa. We used the well-characterized Caco-2 transwell model of the human gut
epithelium (9). In this experiment, a monolayer of Caco-2 gut epithelial cells was grown on a
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transwell membrane, and the ability of naringenin to cross this barrier was measured over time.
When complexed to HPPCD, naringenin reached a concentration 11-fold higher than in the
absence of the excipient. The integrity of the monolayer was verified both at the beginning and
end of the experiment (by measuring the transport of Lucifer yellow), suggesting that neither
HP3CD nor naringenin were damaging to the cells at the concentrations and time-scales
examined.
Lastly, we examined the ability of HP3CD to enhance the bioavailability of naringenin in
a rat model. Two groups of male Sprague-Dawley rats were fed 20mg/kg body weight
naringenin. One group was fed naringenin alone, while the other was fed a HPCD-naringenin
complex. Blood samples at different time points were serially collected and subsequently
analyzed by LC-MS, and tissue specimen was collected immediately after animals were
sacrificed for histological analysis. Our results indicate a substantial improvement in the
delivery of naringenin complexed with HPPCD, with AUCo-o of naringenin increasing 7.4-fold
and maximal concentration, Cmax, increasing 14.6-fold. This increase in bioavailability represents
an increase in the absorption rate from Ka = 63.7 hr' to Ka = 26.9x10 4 hr1, a 4200-fold increase.
Several effects could explain this increased rate of transport, including enhancement of
dissolution kinetics, increase in solubility, decrease in degradation kinetics in the gut, change in
the properties of the intestinal membrane, and shuttling and enhancement of drug
concentration at the intestinal wall (16). More study is required to distinguish the dominant
mechanisms that lead to enhanced bioavailability in this system. It is unlikely that complexation
with HPPCD changes the plasma pharmacokinetics of naringenin, as cyclodextrins are very
poorly transported across the intestinal wall (17). The calculated half-life for naringenin in
plasma was 2.28 hours, consistent with values previously reported in humans (5) and rats (28).
Previous studies have demonstrated naringenin's low bioavailability, consistent with our
results for non-complexed naringenin. Niopas and coworkers orally administered 135mg
naringenin to six healthy volunteers. Plasma concentrations peaked after 3.5 hours, and
bioavailability was estimated to be 5.8% (11). Erlund and coworkers found similarly low
bioavailability when the source of naringenin was grapefruit juice. The researchers also noted
the high variability in bioavailability, which was hypothesized to be the result of subject-to-
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subject variation in gut microflora (11). The low levels of naringenin plasma concentrations that
have been attained in these trials are significantly lower than those required to attain a
therapeutic effect as measured both in vitro and in animal models. Huff and colleagues have
demonstrated that in human hepatoma-based HepG2 cells naringenin's peak modulation of
lipid metabolism is attained in the range of 100-200tM (2, 14, 18-20). Our recent results
demonstrated that 200pM naringenin blocked the production of HCV in chronically infected
Huh7.5.1 cells, concomitantly with a reduction in VLDL secretion (21). Furthermore, animal
studies that have demonstrated the beneficial effects of naringenin often employ high doses of
the flavonoid (1, 22). Attaining a Cmax of 200M in a human would be equivalent to absorbing of
0.25-0.5g of naringenin (neglecting clearance), illustrating the importance of enhancing the
bioavailability of the flavonoid.
Our results suggest that complexing naringenin with HP$CD would increase the
bioavailability of the naringenin substantially, allowing a smaller dose to be administered, while
still achieving the therapeutic plasma concentrations predicted by in vitro experiments. More
work is required to further elucidate the contribution of several possible mechanisms to the
enhanced transport of naringenin across the intestinal wall.
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5.4 Materials and Methods
Materials
Naringenin, P-cyclodextrin (PCD), methyl f-cyclodextrin (mpCD), and 2-hydroxypropyl-3-
cyclodextrin (HPICD) were purchased from Sigma-Aldrich Chemicals (St. Louis, MO). Caco-2
cells were purchased from the American Type Culture Collection (Rockville, MD). Unless
otherwise noted, all chemicals were purchased from Invitrogen Life Technologies (Carlsbad,
CA).
Solubility curves of naringenin complexed with cyclodextrin
Stock solutions of naringenin were prepared in ethanol. A calibration curve was prepared by
measuring the UV absorbance of the naringenin stock solutions (0.1 to 0.6 mM) at 290 nm using
a ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, DE, USA). Standard
deviations between triplicate measurements were less than 5% (Figure 1A).
Improvements in naringenin solubility when complexed with cyclodextrin were determined and
evaluated as follows. Stock solutions of bCD, mbCD, and HPbCD were prepared in distilled
water. None of the cyclodextrins absorbed at 290 nm for concentrations from 0 to 50 mM
(data not shown). Next, excess amounts of naringenin powder were added to solutions
containing variable amounts of each cyclodextrin, vortexed, and incubated with shaking at 37*C
for 3-5 days. Naringenin-cyclodextrin solutions were filtered through a 0.45 tm filter to remove
the undissolved naringenin, diluted by 20 or 50-fold, and absorbance was measured at 290 nm.
The complex stability constant K was calculated from the linear portion of the solubility diagram
assuming a 1:1 complex, that the concentration of free naringenin is equivalent to 36 M
(solubility in absence of cyclodextrin), and using the equation:
K [eq Naringenin * CD I
[Naringenin I [CD]
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Caco-2 cell culture
Caco-2 human epithelial colorectal adenocarcinoma cells were cultured in tissue culture flasks
(Becton Dickinson and Co., Lincoln Park, NJ). The growth medium was Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum, 1% nonessential amino acids, and
4 mM glutamine without antibiotics. The monolayer cultures were grown in a humidified
incubator at 37"C and 5% CO2. The cells were harvested with 0.25% trypsin and 0.2% EDTA (0.5
to 1 min at 37*C), resuspended, and seeded into a new flask. Cells between 30 to 53 passages
were used.
Intestinal transport assay
For the transport studies, Caco-2 cells were seeded on Transwell (0.4-pm pore size, 1-cm 2
growth area; Corning Costar Co.) at a cell density of 1x105 cells/filter. Cell growth and
maintenance were kept as previously described (23). The cell monolayer was fed fresh growth
medium every 2 days and was then used on Day 21 for the transport experiments. To evaluate
the integrity of the monolayer, transepithelial HBSS supplement with 20 mM d-glucose and 10
mM HEPES (pH 7.35) was used as the transport medium. To determine the amount of drug
crossing the polarized Caco-2 cell monolayer from the donor to the receiver (i.e., apical to
basolateral), the Caco-2 cells were rinsed twice with pre-warmed transport medium and were
incubated by pre-warmed transport medium 0.2 ml for apical chamber and 0.5 ml for
basolateral chamber at 37 *C for 30 min. A 60 mg/ml (1% DMSO in HBSS) stock solution of test
compounds, either naringenin or HPjCD-naringenin, was added and samples from both apical
and basolateral were taken (30 pl) at different time points: 30, 60, 120, 150 180, 240, and 300
min. The integrity of the culture was confirmed microscopy and by detecting fluorescently
labeled cells using 60pM of Lucifer Yellow as a standard. The concentrations of naringenin or
HPPCD-naringenin were determined as described and plotted as a concentration on the
basolateral side vs. time. Concentrations were corrected by the dilution factor as fresh buffer
was added after sampling.
Animal experiments
Adult male Sprague-Dawley rats were purchased from Charles Rivers Laboratories (Wilmington,
MA). Upon arrival, each rat was isolated for 5 days towards adaptation to the new
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environment. Animals were housed under 12h cycle of day/night with free access to drinking
water and fed ad libitum. Briefly, rats weighing between 280 and 300 g were anaesthetized
using intraperitoneal injections of ketamine and xylazine at 110 and 0.4 mg/kg, respectively.
The left carotid artery was cannulated using a 0.76-mm diameter x 60-cm length heparanized
catherter. The catheter was tunneled subcutaneously from the opening made in the anterior
face of the neck to the dorsal site of the neck and permanently anchored in the skin. The
catheter was secured by the use of a rat jacket. Animals were placed in their cages during the
term of the study. Animals were orally administered with 20 mg/kg body weight of naringenin
in either water or complexed with 320 mg/kg body weight HPbCD using a rat oral gavage (18G x
11/2" plastic feeding tube from Instech Laboratories, Inc, PA, USA). Blood samples (0.5 ml)
were collected at 0, 15, 30, 60, 120, 240, 360, 510, and 600 min from the carotid artery using
the previously placed catheter. In two additional experiments, animals were placed in
metabolic cages and urine was collected a pooled for the duration of the experiment. All
animals were treated in accordance with National Research Council guidelines and approved by
the Subcommittee on Research Animal Care at the Massachusetts General Hospital.
LC-MS detection of naringenin
LC-MS analysis was performed on an Agilent Technologies series 1100 LC-MSD system (Santa
Clara, CA), which included an Agilent 1100 quaternary pump, autosampler, column oven, on-
line vacuum degassor, and single quadrupole mass spectrometer equipped with electrospray
ion source (ESI).
Mass spectrometry conditions: Electrospray ionization (ESI), positive, selected ion monitoring
scan (SIM); SIM: naringenin m/z 273.1; IS (hesperetin) m/z 303.1. LC conditions: Eclipse XDB-
C18 column (4.6x150mm, 5.0km). The mobile phase was composed of methanol-water with
0.1% formic acid (65:35,v/v). The isocratic flow rate was set at 0.8 ml/min and injection volume
was only 10 1.
To each 100 Id of rat serum sample, 100 |l of 0.1N sodium acetate (pH=5.0) and 100 [tl of @-
glucuronidase enzyme (5000 units/mL, type HP-2 from Helix Pomatia) were added and vortexed
for 5 seconds. This process hydrolyzes the conjugated form of naringenin to determine total
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naringenin in plasma. After addition of 20 1tl IS buffer solution (5 [tg/mL), the sample was then
incubated at 370C water bath for 18h.
The sample was extracted with 0.8mL of ethyl acetate after 18 h incubation, and centrifuged at
13000rpm for 10 min. The supernatant was collected and evaporated to dryness under nitrogen
at room temperature. The residue was reconstituted with 100 |d of mobile phase and filtered
through a micro nylon n filter (0.45 rim). 10 ld of the filtrate was forwarded to LC-MS analysis. A
calibration curve was established and QC samples conducted (data not shown). Data acquisition
was performed using ChemStation software (Agilent). Linear regression (weighted by 1/x)
between serum concentration and peak area ratio of naringenin to IS was constructed using
SPSS11.0 statistical software. The concentrations of naringenin in samples were calculated by
interpolation of the linear equation.
Liver Histology
Histological sections of each organ were taken 10 hours after treatment. Formalin-fixed,
paraffin-embedded liver, intestine, and kidney samples were sectioned at 4 tm and stained
with hematoxylin & eosin (H&E). Histological characterization was performed by a blinded
observer using standard assessment of damage.
Modeling naringenin transport in the gut
In this model, the first compartment represents the lumen, and the second compartment
represents the circulatory system. These two compartments are governed by the following
mathematical equations (16):
dL
=t -k,[L]dft
dC
-= k[L] -k2[C]
dt
Here we assume that the cyclodextrin is absorbed through the lumen [L] at a rate of ki, and
cleared from the circulation [C] at a rate k2; and that there is no loss of cyclodextrin in feces,
and thus all orally administered cyclodextrin will pass through circulation. In order to obtain the
values for ki and k2, we fit the response of [C] which is the amount of naringenin in the
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circulation, assuming that the initial amount of naringenin in the lumen is assumed to be 5 mg.
We further assume that the primary difference between the two cases is captured by k1
reflective of the increase in transport of naringenin across the lumen due to the formation of a
complex with cyclodextrin, whereas k2 which is reflective of naringenin clearance from
circulation is constant.
Modeling was done using MATLAB, and code for curve fitting is given in Appendix 1.
Statistics
Data are expressed as the mean t standard deviation. Statistical significance was determined
by a one-tailed Student's t-test. A P-value of 0.05 was used for statistical significance.
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6 Conclusion
6.1 Summary of results
We began our work by examining the link between VLDL and HCV secretion. We
demonstrated that HCV was secreted while physically bound to ApoB and that HCV
secretion mirrors that of VLDL. We went on to show that HCV core colocalizes with
ApoB in the cell, and that inhibition of ApoB production through RNAi could block viral
secretion. Notably, concurrently with our work, several other laboratories were
conducting research along similar paths, establishing firmly the dependence of HCV on
the secretion of VLDL from hepatocytes (1-3).
The close association of VLDL and ApoB secretion led us to search for an agent
that could effectively reduce VLDL secretion. Naringenin, a grapefruit flavonoid, seemed
like a promising candidate, as it had been shown earlier to block VLDL secretion in in
vitro models (4-6), and to lower plasma VLDL levels in vivo (7-10). We therefore showed
naringenin inhibited ApoB and HCV secretion concomitantly. We went on to investigate
how naringenin was interfering with the viral lifecycle and narrowed it to the assembly
step - the flavonoid was interfering with a later step than protein production and
replication, but earlier than export.
We next hypothesized that naringenin reduced the components needed for the
production of VLDL. Indeed, we showed that naringenin inhibited MTP, the rate-limiting
enzyme in the production on VLDL. Unlike other MTP inhibitors, we did not see an
accumulation of triglycerides in cells treated with naringenin (11). These results, as well
as observations of other groups, led us to hypothesize that naringenin was activating
the PPARc nuclear receptor (NR). In the liver, PPARc drives f-oxidation, leading to the
breakdown of lipids - components required for VLDL production. We showed that
naringenin activates PPARc in HCV-infected cells and that a known PPARct agonist,
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WY14,643, had similar inhibitory effects on virus production as naringenin. A 7-day
experiment confirmed that naringenin's effects were sustainable, but that withdrawal of
treatment leads to a quick rebound in virus production, consistent with our proposed
mechanism of action.
We next investigated in more depth the effects of naringenin on NRs. We
suggested that naringenin could be modulating the activity of two nuclear receptors
(NRs): PPARc and LXRa. LXRa is a pro-lipogenic NR that is activated by oxysterols and
glucose, and that drives the production of lipids and cholesterol. We showed that
naringenin activated PPARc, and the related PPARy in reporter cell systems. We further
showed that naringenin suppressed the activation of LXRa in reporter cells.
Interestingly, a biochemical assay indicated that naringenin functioned as a partial
agonist of LXRa, leading to a net inhibitory effect in cells. We confirmed the effects of
naringenin on PPAR- and LXR-response elements using reporter plasmids transfected in
Huh7.5.1 cells. To understand the effects of this activation at the levels of gene
activation and metabolic effects, we first showed that naringenin activated PPARa-
controlled genes involved in p-oxidation and downregulated LXRa-controlled genes. We
then demonstrated that in primary rat hepatocytes, naringenin decreased the secretion
of triglycerides and bile acids from cells, and that WY16,463 inhibited ApoB secretion
similarly to naringenin.
Lastly, we wished to explore the possible utility of naringenin in a clinical setting.
We demonstrated that the flavonoid was non-toxic to primary human hepatocytes in
culture and to rats administered high doses intraperitoneally, consistent with the
observations of others regarding its low toxicity. We then showed that naringenin's
solubility and bioavailability could be dramatically increased by complexation with p-
cyclodextrin.
In summary, we have shown naringenin's potential to inhibit HCV production in
cells. We have characterized the mechanism of this inhibition, tracing it to interference
with VLDL assembly. We then showed that this effect on VLDL could be traced to the
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flavonoid's effects on NRs. Finally, we demonstrated a method of increasing any future
clinical utility of the molecule by enhancing its bioavailability.
6.2 Impact
We believe this work may have a large impact on the treatment of HCV. Naringenin is a
cheap molecule and has a history of safe use as a food supplement. It could be used as a
weapon in the arsenal against HCV, most likely in combination with other drugs.
Importantly, our work helps establish ground for further investigation of
methods of modulating metabolism to target HCV and possibly other pathogens. It also
demonstrates the value of studying naturally derived molecules for beneficial clinical
effects.
6.3 Future directions
Our work thus far has focused on the in vitro effects of naringenin - we would also like
to examine the effects of naringenin in an in vivo model. Unfortunately, few options
exist for HCV animal models: either chimpanzees or chimeric mouse models. The latter
carry grave ethical and cost considerations, while the latter are more feasible, but less
complete. Especially in the context of nuclear receptors, it is not clear that the
responses observed in these models would be applicable to human patients.
Of course, the ultimate test of our work would be application to patients. We
look forward to the possibility of conducting small clinical trial to examine the effects of
naringenin in HCV-infected patients. An early target population would consist of
patients who do not respond to the standard of care, and would likely be administered
in combination with other medications. It will be important to establish whether the
expected reduction in HCV production by hepatcytes will lead to improvement in clinical
outcomes, and whether the treatment and its outcomes are truly sustainable over
months and years.
Our work also sets the stage for examining the effects of other flavonoids and
natural products as possible modulators of metabolism, and thus of the HCV viral
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lifecycle. Furthermore, evidence that hepatitis B virus proteins modulate LXRa activity
(12, 13) suggests that the interaction between hepatitis viruses, lipid metabolism, and
nuclear receptors is not unique to HCV, thus expanding the potential of naringenin to
treat other infections as well.
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Appendix I
MATLAB Code for Modeling
clearance test.m
clear all; close all;
global data;
data = [2988.5 4255.7
2502.3
2182.9
2604.8
1968.8
2370.0
948.1
434.8
4616.2
2276.9
2062.0
1177.4
1675.3
1204.3
940.3 258.0
5259.0
1570.4
435.9 53.8
376.7 101.1
568.2 166.7
1572.6
915.3 172.1
164.6 71.8
p = fminsearch(@clearance fit, [26.7502 0.8100 0.0460]);
55.7
92.2
157.4117.4
55.6
301.5
197.0
311.9
307.5
211.6
46.2
94.9
392.8
325.9
173.8
118.1
95. 9
272.9
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clearance.m
function dx = cl
global ci;
global c2;
dx(l) = -1*
dx(2) = cl *
dx = dx';
clearance fit.m
functi
global
global
global
global
on error
ci;
c2;
c3;
data;
earance (t, x)
cl * x(1);
x(1) - c2 * x(2)
= clearance fit(p)
cl = p (1)
c2 = p(2);
c3 = p(3)
tp = [0.25, 0.5, 1, 2, 4, 6, 8.5,
[t,x] = ode23s(@clearance, [0 10]
flag = false;
xp = interpl(t,x(:,2),[0.25, 0.5,
xp = xp';
ff = mean(data(:,1:3)')';
error = norm(data(:,1) - xp);
%plot(t,x, tp, data(:,1:3));
10];
[5000,0]);
1, 2, 4, 6, 8.5, 10]);
cl = p(3);
[t2,x2] = ode23s(@clearance, [0 10], [5000,0]);
x2p = interp1(t2,x2(:,2), [0.25, 0.5, 1, 2, 4, 6, 8.5, 10]);
x2p = x2p';
ffx = mean(data(:,4:6)')';
error = error + norm(ffx - x2p)
plot(tp, data(:,2), t, x(:,2), tp, ffx, t2, x2(:,2));
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